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ABSTRACT
The production of materials at the nanoscale leads to novel properties and has
made the field of nanotechnology a part of everyday life. Numerous applications of
nanomaterials have led to their use in electronics, optics, and medicine. However,
creating materials at such a small size brings them on the same scale as many
biomolecules and cellular components, altering their interactions with biological systems.
This can lead to unintended biological impacts as many nanomaterials are considerably
more toxic than their bulk counterpart material. ZnO nanoparticles (nZnO) are
particularly interesting in this context. The FDA classifies ZnO as a generally recognized
as safe substance, but numerous reports have demonstrated that they are inherently toxic
when produced in the nanoscale. Much research has been conducted on understanding
what makes them toxic in order to modify their properties for specific applications. While
this would seem to impede their commercial use, many of the properties that make nZnO
toxic have been exploited for the treatment of various diseases.
A wealth of knowledge has been generated about the physicochemical properties
of nZnO that contribute to their toxicity, yet controversy remains about the toxicity
mechanism. Numerous factors contribute to the toxicity of nZnO and the mechanism can
vary greatly between cell types and the properties of the nanoparticles (NPs) under study.
Even with all the data available, more work is needed to understand the complex
interplay of nZnO with cells to fully exploit their commercial use and development as a
potential therapeutic. In this regard, studies described in this dissertation were conducted
vii

to help further the understanding of what aspects contribute to the cytotoxicity of nZnO
and how different properties of the material can be utilized for biological applications.
The first chapter demonstrates that biological buffers can significantly impact the
dissolution property of nZnO and may influence the conclusions that have been drawn
from previously reported studies. All the biological buffers tested, including HEPES and
MOPS that are routinely utilized in cellular media and biological imaging solutions,
induced the rapid dissolution of nZnO. This observation extended to other experiments
that demonstrate the inclusion of biological buffers in commonly used RPMI media,
impacted the conversion of nZnO to other chemical species and altered its structural
morphology. As dissolution has been implicated as one of the primary sources of nZnO
toxicity, cellular viability experiments were conducted and the inclusion of HEPES in the
media was found to significantly increase the toxicity of nZnO towards leukemic Jurkat T
cells. These results highlight the fact that environmental factors need to be carefully
considered when assessing the toxicity of nZnO.
Ion channels are critical to a cell’s ability to maintain homeostasis and are
imperative for the correct functionality of many cells. Therefore, the second chapter
focused on what effects nZnO may have on transmembrane transport. For these
assessments, lysenin, a pore forming toxin that mimics ions channels with respect to ionic
transport and regulation, was utilized to investigate potential interactions of protein
channels with nZnO. The conductance of lysenin was greatly diminished in the presence
of nZnO and is believed to depend on electrostatic interactions. Lysenin’s conductance
can be inhibited from zinc ions, but the dissolution of nZnO was ruled out as being
responsible for the modulation of the transport capabilities of the protein. We concluded
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that the positively charged nZnO interacts with negative residues within lysenin to alter
the conductance and these observations may translate to a potential contributor to the
cytotoxicity of nZnO.
Many of the assessments on nZnO toxicity have relied on end-point observations.
This is due, in part, to the fact that their small size makes it extremely difficult to track
their interplay with cells in real-time and fluorescent labeling of the NPs may alter how
unmodified nZnO interacts with cells. Direct fluorescence imaging of the NPs could
substantially help in tracking the complex interactions of nZnO with cells. However, the
band gap of nZnO is 3.37 eV which correlates to 368 nm and therefore requires the use of
UV excitation sources to generate photo emissions. Unfortunately, UV excitation sources
and detectors are generally absent in most conventional fluorescence microscopes making
this approach difficult. The third study of this project sought to modulate certain physical
properties of nZnO to create a way to fluorescently track the NPs in living cells without
changing the composition of the material. To achieve this goal, a systematic control of
defects in the crystal of nZnO was carried out to alter its properties. By producing a
relatively high number of defects in nZnO, the band gap of the material was lowered to
~3.1 eV (400 nm) and produced a narrow emission in the visible spectra, with a peak at
425 nm. These changes allowed for the use of a 405 nm laser, generally available on
fluorescent microscopes, to image the nZnO with confocal microscopy. Initial live-cell
imaging experiments were conducted to demonstrate the feasibility of utilizing these new
nZnO to track their interactions with cells.
The final piece of this dissertation sought to utilize the ability of nZnO to generate
ROS when photo irradiated for a new drug delivery platform. Towards this end, the nZnO
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were encapsulated within a lipid coating and in vitro studies demonstrated that the
encapsulation of the NPs essentially removed the toxicity at concentrations up to 10 times
the IC50 of bare nZnO. This feature could be extremely helpful in preventing off-target
effects when treating patients with nZnO but requires reestablishing the toxicity when the
NPs reach the cancerous environments. To this end, the cancer cells that were treated
with the encapsulated nZnO were exposed to irradiation and the cytotoxicity of the NPs
was restored. To further expand upon this strategy, a fluorescent dye was co-encapsulated
with the nZnO to simulate hydrophilic drug loading and allow for evaluations on the
ability to trigger the release of the dye. Studies on the release kinetics demonstrated a
rapid release of the dye upon irradiation and gave insights into optimizing the
encapsulation of the NPs. To demonstrate that this strategy is not just a novelty of
fluorescent dyes, the hydrophobic chemotherapy drug Paclitaxel was co-encapsulated
with nZnO. Both Jurkat T cell leukemia and T47D breast cancer cells were treated with
the co-encapsulated nZnO and Paclitaxel. In both cases, the triggered release groups
showed improved toxicity towards the cells with the most pronounced difference noted
for the breast cancer cells. Taken together, the cumulation of this dissertation helps
further the progress in understanding the cytotoxicity of nZnO, offers a new way to study
the interactions of essentially pure nZnO with cells and provides a novel strategy for the
use of nZnO as a therapeutic and potential diagnostic tool.
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CHAPTER ONE: INTRODUCTION
Overview of Nanomaterials and ZnO
The field of nanotechnology is growing at an extraordinarily fast pace with
industries and governments spending billions of dollars per year in basic research and
development. Producing materials in the nanoscale (0-100 nm) creates novel properties
that are not observed in bulk (micron sized or larger) material of identical composition.
The changes in the material properties can be largely attributed to the small size, where a
relatively large fraction of the atoms comprise the surface compared with the atoms
found within the volume of the material. Not only do new properties emerge, but the
reduction of the material size brings them on the same scale as many cellular components
and biomolecules. These features alter the material’s interactions within biological
systems and have been exploited for numerous applications.
ZnO nanoparticles (nZnO), in particular, are mass produced and used worldwide
with an estimated market valued at $2.099 billion in 2015 with an expected market value
of $7.677 billion by 2022.1 The novel properties of nZnO have led to their use in
cosmetics, electronics, an anti-bacterial and anti-fungal agents, as well as a potential
cancer therapeutic.2-8 While their production at the nanoscale offers much promise in
numerous fields, there is also concern about their unintended biological impacts. The
FDA classifies ZnO as a generally recognized as safe substance, but when produced in
the nanoscale, many reports have demonstrated a relatively high toxicity towards various
cell types.9-12 This underscores the reason why many researchers have sought to
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understand what makes nZnO toxic with the hopes of tailoring its properties to reduce its
toxicity or manipulate these features for the treatment of various infections and diseases.
Toxicity Mechanisms of nZnO
The inherent cytotoxicity of nZnO has been studied with numerous cell types
including mammalian primary and cancer cells, bacteria and fungi.5, 13-16 Studies have
extended to in vivo systems in various mammals, zebra fish and crustaceans.17-20 Even
though numerous reports on nZnO toxicity have been published, the mechanism(s) of
toxicity still remains controversial. There are two mechanisms that have been identified
as the important sources of toxicity; reactive oxygen species (ROS) generation and
dissolution of the nanoparticle.
Dissolution of nZnO results in the release of ionic zinc, which can disrupt
homeostasis and eventually lead to cell death.21, 22 Even within this context there is
controversy in regards to how dissolution leads to cytotoxicity. One proposed route is that
large amounts of ionic zinc are released in the extracellular environment and are then
internalized by the cells. This can occur through zinc specific transporters called the ZIP
(SLC39) family, via non-specific ion transporters, or through endocytosis.23-25 For
example, Johnson et al. demonstrated that up to 37% of available zinc from the nZnO
under study was released after suspension in the cellular media DMEM.26 Treatment of
the cells with the NP suspension induced cell death and the authors concluded that uptake
of extracellular zinc ions was responsible for the toxicity. This was supported by two
different experiments. Pre-treatment with EDTA, a known zinc chelator, abolished the
toxicity, and treatment with levels of CaCl2 that inhibit calcium channels, which are
partially responsible for zinc uptake, reduced the toxicity of nZnO.
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In contrast, other researchers have proposed that the large increases of
intracellular zinc stem from endocytosis or passive transport of nZnO into the cell. Once
internalized, the nZnO that passively entered can shed the zinc ions within the cytoplasm
directly. For the endocytic route, the endocytosed vesicles fuse with lysosomes, which
contain a low pH, and rapidly dissolve the nZnO which subsequently releases the free
zinc ions within the cell. A report on nZnO interactions with human colon carcinoma
cells showed extensive nanoparticle entry into the cells after just one hour.27 The entry of
the nZnO was believed to be from both passive entry and endocytosis. After the first
hour, the number of nanoparticles inside the cells apparently decreased. However, a
complementary study showed that the levels of free zinc inside the cells correlated well
with the decrease in the number of intact nZnO from a sustained dissolution process.
Similarly, a report that treated human bronchial epithelial cells with nZnO showed high
levels of intracellular ionic zinc but the large concentrations of ionic zinc were recorded
after just one hour.28 To try to determine how the intracellular zinc entered the cell, they
treated the same cells with nZnO doped with iron, as it had a much slower dissolution
rate. From the slower dissolution rate, they were able to track that the doped nZnO were
internalized into the cells and concluded the undoped nZnO internalized first, but rapidly
dissolved to cause the increased ionic zinc concentrations.
Regardless of how zinc ions enter the cell, disruption of zinc homeostasis can
quickly lead to cellular death. Chevallet et al. investigated how human liver-derived cells
(HepG2) responded to treatment with nZnO and zinc acetate.29 At non-lethal doses, the
cells tried to regulate the influx of zinc ions through large increases in Metallothionein
1X, a protein that chelates zinc ions to combat metal toxicity, and Znt1, a protein
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responsible for the efflux of zinc from the plasma membrane. The authors provided
evidence that the cells transport and store the excess zinc in the mitochondria. At critical
levels, the excess zinc leads to mitochondrial injury and can eventually lead to the
triggering of apoptosis.
The other strongly argued mechanism of toxicity is due to the generation of ROS,
although some controversy regarding the precise mechanism of ROS generation remains.
Some argue that the dissolution process of nZnO triggers apoptosis, as discussed above,
that in turn creates the heightened levels of ROS found within the cell. Supporting
evidence for this model utilized the mouse macrophage Ana-1. The authors measured the
amount of free zinc ions in the media and concluded that the zinc ions were responsible
for the observed increases in ROS levels due to the cytotoxic response.30 Shen et al.
similarly concluded that ROS generation was a consequence of high intracellular ionic
zinc levels but that this only occurred after nanoparticle entry into the cell.31 While there
is certainly evidence that points to this route of ROS generation, other researchers have
demonstrated that nZnO can produce ROS intrinsically.
The inherent ability of nZnO to produce ROS is related to the band structure of
the material. The valence band is the highest energy level that an electron occupies when
bound to the material. In metals, the valence band overlaps with the conduction band
allowing electrons to act as free charge carriers. For semiconductors such as ZnO, the
minimum energy required to excite an electron from the valence band to the conduction
band is termed the band gap. When enough energy is supplied to the electron, it can move
into the conduction band and becomes a “free” electron. However, the free electron can
become bound to the hole left in the valence band and these electron hole-pairs are
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termed excitons. Due to the small size of nZnO and surface defects, a relatively large
number of excited electrons and excitons can be stabilized in the material.32, 33 The
conduction band electrons and valence band holes are proposed to be responsible for the
ability of nZnO to catalyze the production of ROS.
The ability to intrinsically produce ROS stems from two different processes.34
The excited conduction band electrons are thought to react with adsorbed O2 molecules
and form superoxide anions. The holes left in the valence band react with locally
adsorbed OH- ions to produce hydroxyl radicals. In the context of cytotoxicity,
superoxide anions (O2-) can then be converted by the enzyme superoxide dismutase to
form hydrogen peroxide. Due to the stabilization of excitons from the small size of the
particles, nZnO can catalyze ROS production leading to cytotoxic effects. These ROS
generating capabilities of nZnO are further enhanced by irradiation with UV light, as it
provides more energy than the band gap of the material.34 Photoirradiation excites the
valence band electrons into the conduction band, thus rapidly accelerating the intrinsic
ROS production of the nanoparticles.
Dissolution and ROS production from nZnO are considered two of the primary
mechanisms of nZnO cytotoxicity. As previously discussed, there are obviously
conflicting reports about the toxicity mechanism of nZnO and even within the context of
a specific mechanism, there is no clear consensus. These mechanisms are not necessarily
independent and are all likely to contribute to the interactions of nZnO with cells. A
recent report investigated how variously synthesized nZnO generated different toxicity
profiles.35 Many key physical properties of the nanoparticles were similar such as crystal
size, band gap and lattice parameters but other factors such as hydrodynamic size,
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dissolution potential and ROS generation were different. This report highlights that even
though the same material, nZnO, is utilized in the various studies, variations in the
physicochemical properties impact the nZnO interactions with cells and may alter the
toxicity mechanism.
Factors that Impact Toxicity
With all the reports regarding nZnO toxicity, it has become apparent that the
physicochemical properties of the material can impact nZnO interactions with cells.
Making matters more complex is the fact that different cell lines will also interact with
nZnO in unique ways. As discussed previously, even in the context of dissolution there
remains controversy. Researchers utilizing RAW 246.7 macrophages, a phagocytic cell
line, concluded the uptake of the nanoparticles is largely responsible,36 and yet other
researchers using non-phagocytic cell lines suggest that extracellular dissolution induces
cell death.29 While extreme differences between cell lines will impact interactions with
nanoparticles, more basic cell growth characteristics have also been shown to impact cell
viability.
Cho et al. demonstrated that sedimentation of nanoparticles impacts the uptake of
the particles by cells.37 The sedimentation of the NPs to the bottom of the cell culture
well creates higher concentrations of the particles on the cell surface compared with the
initial bulk concentration introduced into the media.37 To illustrate this point for nZnO, a
study was conducted that created a more stable dispersion of nZnO in media by first
coating the particles with serum proteins.38 When an adherent cell line was treated with
the particles, the more stable suspension resulted in increased viability, presumably by
reducing the amount of nanoparticles settling on top of the cells. In contrast, Jurkat T
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cells, a suspension cell line, showed the opposite trend. The more stable solution
increased the interaction of the nanoparticles with the suspended cells, thereby reducing
the viability. This study demonstrates how other factors can influence the viability studies
of nZnO and the coating of NPs with serum proteins highlights another factor that plays a
role when determining nanoparticle toxicity.
One well known factor that alters nanoparticles in biological studies is the
formation of a protein corona around the particles. Much work has been done to
understand how biological media (e.g. plasma) interacts with nanoparticles. Studies have
shown that regardless of the nanomaterial’s bulk composition, the particle surface
properties and size influence the corona formation.39 The corona can be categorized into
two sub-classes; the hard corona, comprised of biomolecules with a high affinity for the
nanoparticle surface, and a soft corona that is made of molecules that rapidly exchange
from the surface back into the media. This corona formation likely impacts the interaction
of nanoparticles with cells, and depending on the attached biomolecules, may alter
endocytic or passive transport mechanisms. As different cellular media compositions
utilize various serum proteins, this fact also highlights the importance of the environment
the study is being conducted in.
Not only do serum proteins interact with nanoparticles, but certain components in
cellular media used for in vitro studies have also been shown to play a role. As nZnO are
prone to dissolution, the zinc ions that are released interact with the carbonate in media,
forming insoluble zinc carbonate species.40 Phosphate is another common component in
cellular media and varies in concentration between different media formulations. This is
important as it has been shown to react with nZnO. Over time, phosphates induce the
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transformation of crystalline ZnO to porous structures comprised of both crystalline and
amorphous zinc oxide and zinc phosphate species.41, 42 As these studies are more recent,
only a few evaluations have considered how these new chemical species impact the
toxicity of nZnO. Additionally, when drawing conclusions on the impact dissolution of
nZnO has on the toxicity, the formation of insoluble precipitants from various
concentrations of phosphates and carbonates impact the “free” zinc ion concentration in
the extracellular environment. This fact may be a common reason why conflicting reports
exist regarding the toxicity mechanism of nZnO. Taken together, it is apparent that the
complex nature of deciphering the toxicity of nZnO needs to take into account the
physicochemical properties of the nanoparticle and also how the various components in
the study environment alter their interactions with various cell types.
Bioimaging
Fluorescent and luminescent imaging have helped to produce a wealth of
knowledge about cell structure, dynamic cellular processes and trafficking. The
development of quantum dots, inorganic nanoparticles that are fluorescent due to changes
in their physical properties, have emerged as an exciting new technology for bioimaging
studies. When compared to traditional fluorescent organic dyes, quantum dots have many
superior properties such as the ability to alter the excitation and emissions based on the
crystal size, resistance to photobleaching, high fluorescent quantum yields and broad
absorptions.43, 44 Other properties such as large cross sections for two photon microscopy
studies make them beneficial for specific types of studies.43,44
Many of the currently used quantum dots are semiconductors comprised of
cadmium chalcogenides and are well known for the emission tuning through control of
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their size and narrow emission spectra. Since quantum dots have many beneficial optical
properties, they have been used for various imaging applications. However, numerous
reports have also shown that they are highly toxic to cells, reportedly in the nanomolar
range.45 To overcome this limitation, numerous strategies have been employed to reduce
their toxicity. The most common way to reduce the toxicity of quantum dots has been to
coat their surface. However, in a review on quantum dot toxicity, some researchers have
demonstrated that the coating significantly reduces the toxicity of the quantum dots,
whereas others have contributed the toxicity to the coating material that was used to
stabilize the particles in solution.46 While these modifications have allowed for their use
in imaging, researchers have sought out other less toxic semiconducting nanoparticles for
use in bio-imaging.
ZnO nanoparticles have been regarded as a promising candidate for imaging. This
is in part due to their low cost of manufacturing and relatively low toxicity compared to
cadmium-based quantum dots. However, various challenges are present when trying to
use nZnO for bio-imaging. Since the band gap of nZnO is ~3.37 eV, UV light is required
to excite the nanoparticles and they generally emit light in the UV region (~370 nm) from
near band edge emissions and a surface defect related broad green emission (500-700
nm). This broad green region has been targeted by researchers as it is in the visible
spectrum but, unfortunately, its emission can overlap with various other fluorophores
traditionally used in fluorescence imaging studies. On top of this, as discussed above,
ZnO is prone to modifications when introduced into biological medial, such as
formations of zinc phosphate/carbonate species that can quickly quench the fluorescence
generated due to surface defects.
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Many of these challenges have been overcome through various modifications of
nZnO. These modifications include coating the nanoparticles with polymers,
encapsulating fluorescent dyes within nZnO, or doping of various other metals into the
crystal lattice.47-49 While these approaches have created novel fluorescent particles, when
trying to assess the toxicity mechanisms of nZnO, these modifications can alter the
properties of the nanoparticles. Therefore, the conclusions drawn from these particles
may not accurately reflect how unmodified nZnO interacts with cells.
In addition to fluorescence imaging, nZnO have been used for other bio-imaging
applications such as MRI and CT scans.48, 50 In order to accomplish this, one approach
has been to dope nZnO with different lanthanides such as gadolinium as it has a relatively
high number of unpaired electrons and most of the currently used MRI contrast agents are
gadolinium based. Liu et al. demonstrated that Gd doped nZnO particles can
fluorescently label HeLa cells and that T1-weighted MR images of the same cells were
significantly brighter and therefore have potential to be used as a MRI contrast agent.48
Others have shown similar results when testing Gd doped nZnO for MRI purposes and
have also assessed their ability as a possible CT contrast agent.50 Since there have been
recent concerns about side effects from more traditionally used contrast agents, nZnO
holds promise as a viable alternative.
nZnO as a Potential Therapeutic
The selective destruction of cancerous cells is the primary goal for cancer therapy.
In this regard, nZnO are very promising. Numerous reports have not only demonstrated
the toxicity of nZnO to cancer, but have shown high selectivity. For example, one report
demonstrated that nZnO was 33-fold more toxic to Jurkat T cell leukemia than normal T
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cells.10 Others have shown the selectivity of nZnO for cancerous cells of the lungs,
glioma, prostate, breast, blood, nasopharynx and cervix.51-54 Not only has the selectivity
of nZnO been demonstrated with multiple cancer cell lines, but importantly, the
selectivity of nZnO has been demonstrated for cancers such as squamous cell lung cancer
and pancreatic adenocarcinoma in mouse models.17, 55
The selective nature of nZnO is very interesting yet the specific reason for its high
selectivity is still currently unclear. A proposed reasoning for this selectivity has to do
with the fact that ROS is found at higher concentrations in cancerous cells.56 When
cancer cells are challenged with nZnO, the cells tends to generate more ROS than normal
cells. The relatively lower amounts of ROS found in normal cells may allow for them to
mitigate the increase in ROS production when exposed to nZnO and, therefore, protect
them from the cytotoxic effects. Regardless if ROS production stems from nZnO directly
or is a consequence of nZnO dissolution, this may be a possible explanation for why
nZnO are selectively toxic to cancer.
The natural selective nature of nZnO makes it a promising candidate in the
treatment of cancer by itself. However, many researchers have developed strategies to
further utilize certain properties of nZnO and expand its use as a potential therapeutic
option. As nZnO produce more ROS when irradiated with UV light, some have used this
feature to enhance nZnO toxicity towards cancer cells. For example, Hackenberg et al.
showed significant improvement in the ability of nZnO to kill human squamous cell
carcinoma when irradiated with UVA-1 light at concentrations that didn’t affect cell
viability with no light exposure.57 Others have also shown similar increases in toxicity of
cancer cells when exposed to nZnO and irradiated.58, 59 Another strategy has been to co-

12
treat drug resistant cancer cells with daunorubicin, nZnO, and expose them to UV
irradiation. Guo et al. demonstrated synergistically enhanced toxicity of the drug and
nanoparticles when exposed to photoirradiation.60 To expand upon this even further, one
group doped lanthanides into nZnO and demonstrated that instead of UV light, X-rays
could be used to stimulate ROS production from nZnO.50 Not only have the ROS
generating capabilities of nZnO been utilized in the treatment of cancer, but others have
taken advantage of the high dissolution potential of nZnO.
To utilize the dissolution of nZnO in the treatment of cancer, Manshian et al.
optimized the dissolution potential of nZnO by doping iron into the particle.17 They found
that doping nZnO with 2% iron was the optimal concentration and caused selective
cancer cell death both in vitro and in a mouse model. An entirely different strategy that
took advantage of the dissolution potential of nZnO was to utilize it in a drug delivery
platform. The chemotherapy drug doxorubicin was loaded in SiO2 nanoparticles and then
encapsulated with ZnO.61 When exposed to lower pH environments, which is often found
in many tumor microenvironments, the nano-ZnO layer rapidly dissolved and released
the chemotherapy drug. The high dissolution of nZnO at a lower pH has also been used
with porous nZnO as a means to deliver doxorubicin.62 The porous nZnO allowed for
higher drug loading capabilities and the particle was further modified by conjugation of
folate to the surface to actively target breast cancer cells that over express this receptor.
When the drug-loaded particle was exposed to a pH of 5, nearly double the amount of the
drug was released at every evaluated time point when compared to the release profile at
physiological pH (pH=7.4).
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Collectively, the attributes of nZnO have many potential uses as a cancer
therapeutic. With numerous physical properties that can be exploited for drug delivery
applications coupled with the intrinsic cancer cell selectivity, there is exciting potential
for nZnO to be used as a nanomedicine. Additionally, the potential to use nZnO for bioimaging purposes may allow for the creation of novel strategies involving nZnO to treat
patient’s cancer while simultaneously monitoring tumor regression/progression.
Future Directions
The controversy over the toxicity mechanism of nZnO highlights the need to
understand what factors influence the cytotoxic effects. Numerous studies with different
formulation of nZnO and various cell types make arriving at a single conclusion very
difficult. Most likely, multiple modes of action are responsible for the toxicity of nZnO
and is not limited to one factor. Obvious difference in the materials physicochemical
properties, the properties of the cell line and the environment the nanoparticles are being
studied in, can all influence the interactions of the particles with the cells.
Other more modest, yet potentially relevant factors may impact the dynamic
behavior of nZnO within biological systems. To arrive at the point where we can
reasonably predict how the nanoparticles will interact within a specific study would be an
amazing accomplishment, yet, is highly unlikely to occur in the near future with such a
complex system. However, understanding what factors may influence or alter their
interactions is imperative to achieving the safe and effective use of nZnO for its multiple
applications. To achieve these goals, more simplified systems that can isolate one aspect
that influences the nanoparticle toxicity may help in arriving to a more thorough
understanding. With the wealth of knowledge that has already been collected, many of
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the factors that modulate the interactions of nZnO within biological systems have led to
their use in numerous novel ways.
The various attributes of nZnO such as their cancer cell selectivity, low cost of
manufacturing and multiple physical properties that can be harnessed for specific
applications make this an interesting material to research and utilize. The overall goals of
this dissertation sought to further the understanding and use of nZnO within biological
systems. These objectives were to i) understand what factors within biological media can
impact the observed toxicity of nZnO, ii) utilize a simplified model system to understand
the interaction of nZnO with ion channels, iii) develop a way to use unmodified nZnO for
bioimaging studies, and iv) to harness the physicochemical properties of nZnO to be used
in a new therapeutic device. The first two objectives advance our understanding of the
factors that influence the interactions of nZnO with cells and point to a potential new
mechanism that contributes to the cytotoxicity of nZnO. The third objective can
conceivably help in deciphering the complex interplay of nZnO with cells by providing a
means to perform live cell imaging experiments to track the interactions in real-time. It
may also further expand into other potential uses of nZnO, such as its use as a relatively
safer bio-label than more traditionally used quantum dots. The last objective, sought to
exploit the ROS generating properties of nZnO when irradiated to trigger the release of
the nanoparticles and chemotherapeutic drugs. This system provides a potential new way
to simultaneously expose cancer cells to nZnO and chemotherapeutics on demand, while
reducing overall systemic toxicity. All of these studies help the progression of developing
a more thorough understanding of the interplay of nZnO with cells and potentially further
its use as a therapeutic option.
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Abstract
Zinc oxide nanoparticles (nZnO) are one of the most highly produced
nanomaterials and are used in numerous applications including cosmetics and sunscreens
despite reports demonstrating their cytotoxicity. Dissolution is viewed as one of the main
sources of nanoparticle (NP) toxicity; however, dissolution studies can be time-intensive
to perform and complicated by issues such as particle separation from solution. Our work
attempts to overcome some of these challenges by utilizing new methods using UV/vis
and ﬂuorescence spectroscopy to quantitatively assess nZnO dissolution in various
biologically relevant solutions. All biological buﬀers tested induce rapid dissolution of
nZnO. These buﬀers, including HEPES, MOPS, and PIPES, are commonly used in cell
culture media, cellular imaging solutions, and to maintain physiological pH. Additional
studies using X-ray diﬀraction, FT-IR, X-ray photoelectron spectroscopy, ICP-MS, and
TEM were performed to understand how the inclusion of these nonessential media
components impacts the behavior of nZnO in RPMI media. From these assessments, we
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demonstrate that HEPES causes increased dissolution kinetics, boosts the conversion of
nZnO into zinc phosphate/carbonate, and, interestingly, alters the structural morphology
of the complex precipitates formed with nZnO in cell culture conditions. Cell viability
experiments demonstrated that the inclusion of these buﬀers signiﬁcantly decrease the
viability of Jurkat leukemic cells when challenged with nZnO. This work demonstrates
that biologically relevant buﬀering systems dramatically impact the dynamics of nZnO
including dissolution kinetics, morphology, complex precipitate formation, and toxicity
proﬁles.
Introduction
Nanomaterials have generated much attention over the past decade due to the
emergence of novel properties generally not apparent in their bulk micron-sized
counterparts. These novel properties have led to applications in electronics, optics,
antimicrobial materials, and coatings.1−3 Speciﬁcally, ZnO nanoparticles (nZnO) are
highly produced and extensively used in commercial products such as electronics,
cosmetics, and sunscreens.4−7 However, when prepared at the nanoscale size, numerous
recent reports demonstrate high cytotoxicity from nZnO in various cell lines and model
organisms.8−12 The large production volume of nZnO, coupled with an incomplete
understanding of what physicochemical properties contribute to their toxicity, poses a
concern to the environment and public health.13 The mechanism of toxicity is heavily
debated, with multiple factors contributing to the source of cytotoxicity. These
mechanisms are generally thought to depend on physicochemical properties such as size,
dissolution kinetics, and retained surface species.14−17 With such variability in nZnO
properties, numerous mechanisms have been suggested including membrane disruption,
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generation of reactive oxygen species (ROS), and particle dissolution.18−20 Most
researchers recognize the complex nature of deciphering the exact source of cytotoxicity
as multiple mechanisms occur concurrently and vary between cell lines.21−24 Dissolution
is considered a signiﬁcant contributor to the cytotoxicity of nZnO and has been the focus
of numerous studies.25−27 The dissolution properties appear to be inﬂuenced by the size,
shape, defects, and synthesis procedure.28,29 This has established the need to present
detailed physicochemical characterizations of nZnO so that researchers can decipher
ﬁndings and make meaningful conclusions. Studies have shown how biologically
relevant species interact and aﬀect the dissolution properties of nZnO, which has further
confounded the interpretations of complex dissolution studies.26,27,30 Through these
studies, it has been understood that particle dissolution is aﬀected by pH, ionic strength,
adsorption of complexing ligands, phosphate ion concentration, and interactions with
carbonates in the media.28−32 These ﬁndings highlight the fact that the complexity of
toxicity assessments stems from more than the physicochemical properties of nZnO and
requires an understanding of how media components alter their toxicity. Dissolution
studies on particle systems are often carried out by inductively coupled plasma mass
spectrometry (ICP-MS), inductively coupled plasma atomic emission spectroscopy (ICPAES), and atomic absorption spectroscopy (AAS), which are a few of the standards for
quantitative analysis. However, the quantiﬁcation of nanoparticle (NP) dissolution
presents diﬃculties including the physical separation of NPs from the dissolved ionic
species, insoluble precipitant formation, and achieving an equilibrium phase along with
time and cost factors.25,26,33,34 In this work, we attempt to overcome some of these
challenges and present simple methods using UV/vis absorbance spectra and
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spectroﬂuorometric monitoring to measure real-time dissolution kinetics of nZnO
supported by ICP-MS and microscopy techniques. By taking the dissolution results into
consideration, studies on cell viability were performed to determine how common
buﬀering systems aﬀect dissolution kinetics that impacts the structural transformation and
cytotoxicity of nZnO. To our knowledge, no reports exists that address particle
dissolution induced by these buﬀering solutions and the resulting eﬀects that impact NP
toxicity.
Experimental Procedures
nZnO Synthesis and Characterization
ZnO NP samples were produced using the forced hydrolysis method as previously
reported.35 Brieﬂy, zinc acetate was added to diethylene glycol (DEG), and the solution
brought to 80 °C. Nanopure water was added, and the solution was heated to 150 °C and
held for 90 min. Upon cooling to room temperature, the NPs were collected by
centrifugation at 41410g, subsequently washed with ethanol, and the pellet dried
overnight at 60 °C. ZnO NPs where characterized using X-ray diﬀraction (XRD),
transmission electron microscopy (TEM), dynamic light scattering (DLS), X-ray
photoelectron spectroscopy (XPS), and Fourier transformed infrared spectroscopy (FTIR). XRD spectra were collected using a Rigaku Miniﬂex 600 X-ray diﬀractometer, and
the crystal phase, lattice parameters, and average crystalline size determined using
Rigaku PDXL software version 1.8.0.3. NP size distributions were obtained using
randomly selected particles in images obtained from a JEOL JEM-2100 HR analytical
transmission electron microscope. DLS and zeta potential measurements were performed
in nanopure water at a concentration of 1 mg/mL using a Malvern Zetasizer NanoZS.
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Real-Time Kinetics of nZnO Dissolution
Real-time dissolution kinetics measurements were performed using DLS, UV/vis
spectrometry, ﬂuorescence spectroscopy, and conﬁrmed using inductively coupled
plasma mass spectrometry (ICP-MS). For comparison and consistency, all NP stock
solutions were made by suspending nZnO at a concentration of 2.035 mg/mL, vortex
mixing, and sonicating the solution for 10 min. An aliquot of 40 μL was added to 1.92
mL of nanopure water for a ﬁnal concentration of 40.7 μg/mL (∼0.5 mM). All buﬀers
used were prepared at a 0.5 M concentration (except PBS, made at 20×, and sodium
bicarbonate, made at 75 mg/mL) and pH adjusted to 7.4. For each interaction study, 40
μL of each stock buﬀer (100 μL 20× PBS) was added to the NP solution (2 mL total
solution for a 2% overall change in NP concentration) to monitor NP dissolution kinetics.
The Malvern Zetasizer NanoZS was used to qualitatively assess NP dissolution kinetics
in size mode by acquiring 2 runs with 5 s run durations, totaling 180 runs with a 10 s
pause in between runs. Fluorescence spectra were collected at room temperature using a
FluoroMax-4 spectroﬂuorometer with 4.5 mL disposable cuvettes with a working range
of 285−750 nm. Fluorescence spectra were collected with multiple excitation
wavelengths (310−340 nm); however, 310 nm was chosen to eliminate the Raman peak,
associated with water, that would convolute with the nZnO emission spectra when using
higher wavelengths for excitation (see Supporting Information, Figure S2.1). Monitoring
the emission peak at 368 nm yielded a linear correlation between ﬂuorescence and
concentration of nZnO (see Supporting Information, Figure S2.3). For kinetics
measurements, the kinetics mode was used with 310 nm/368 nm ex/em with 2 nm slit
width and 0.5 s integration times. Using the linear correlation, counts per second (CPS)
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were converted to concentration of nZnO in solution. Absorbance spectra were obtained
at room temperature using a CARY 5000 spectrophotometer using 4.5 mL disposable
cuvettes with a working wavelength range of 285−750 nm. Initially, full absorbance
spectra were collected from 290−550 nm. A linear correlation between absorbance and
concentration was also achieved, and dissolution kinetics was obtained by monitoring
absorbance at 368 nm in kinetics mode for consistency (see Supporting Information,
Figure S2.2). For ICP-MS studies, solutions were made by the same procedure but
incubated in Ultracel-4 3k centrifugal ﬁlter units (Millipore) for 20 min. Solutions were
then centrifuged at 4000g for 10 min to remove any NPs and precipitates. A 0.5 mL
aliquot was transferred to 24.5 mL 2% high purity nitric acid solution and analyzed by
the ThermoElectron X-series II quadrupole ICP-MS for determination of total free zinc
ions in solution.
Eﬀects of HEPES on the Behavior of nZnO in Biological Media
To assess the role that HEPES plays on the dissolution properties and fate of
nZnO in biological media, RPMI 1640 (see American Type Tissue Collection (ATTC)
Web site for formulation, www.atcc.org) with and without 10 mM HEPES was used in
these studies. To determine the amount of free zinc ions in solution, ICPMS was
employed to analyze the amount of free zinc in the media at various time points. For this
study, 150 μL of 4.07 mg/mL ZnO NPs was added to 15 mL (40.7 μg/mL overall NP
concentration) of RPMI 1640 (with and without 10 mM HEPES) in tissue culture ﬂasks.
The ﬂasks were then moved into a cell culture incubator at 37 °C and 5% CO2
atmosphere. Two milliliter aliquots were taken out at various time points and transferred
to Ultracel-3K centrifugal ﬁlter units and centrifuged for 10 min at 4000g. Additional
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preparation for ICP-MS studies was performed as described above. nZnO and free zinc
have been shown to form precipitates in media containing sodium bicarbonate and
phosphates. To determine how HEPES in the media inﬂuences the transformation of
nZnO, XRD, XPS, and FT-IR were utilized to characterize NP/precipitate formation in
the media. For basic control reactions, 50 mM ZnCl2 was mixed in solution containing
sodium bicarbonate or PBS to form precipitant and was collected via centrifugation at
41410g and subsequently analyzed by FT-IR (see Supporting Information, Figure S2.9).
For media/nZnO studies, 10 mL of 4.07 mg/mL ZnO NP stock was added to 0.5 L of
RPMI 1640 with and without 10 mM HEPES. The solution was shaken and incubated at
room temperature. At various time points, the solution was centrifuged at 41410g for 10
min. The pellet was washed with nanopure water and dried overnight at 60 °C. For
analysis, a Rigaku Miniﬂex 600 X-ray diﬀractometer was used to obtain the XRD pattern
of the powdered sample, and images were obtained with a JEOL JEM-2100 HR
analytical transmission electron microscope. XPS spectra were collected using a Physical
Electronics Versaprobe system with a monochromated Al Kα X-ray source. The beam
diameter was approximately 100 μm with 25 W of power. For general survey scans, a
pass energy of 117.5 eV was used and for higher resolution core level scans, a pass
energy of 23.65 eV was utilized. Deconvolution of peaks was carried out using OriginPro
2017. FT-IR pellets were produced by grinding 1.5 mg of nZnO/precipitants with 2.000 g
of KBr and pressed with 8 tons of pressure for 4 min. FT-IR spectra were collected using
a Bruker Tensor 27 spectrometer. Deconvolution of the FT-IR peaks was performed
using OPUS 7.0.129. Cell Culture and Viability Studies. To assess the eﬀect that HEPES
has on the cytotoxicity proﬁles of nZnO, the Jurkat T cell line was used as a model
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system. Cells were cultured in RPMI 1640 containing 10 mM HEPES and supplemented
with 10% FBS (fetal bovine serum), 1% penicillin/streptomycin, and 2 mM L-glutamine
per ATCC (American Type Culture Collection, Rockville, MD) recommendation. Cells
were maintained in log phase and seeded at a concentration of 5 × 105 cells/mL in a 96well plate for viability assays. A fresh stock solution of nZnO was prepared for each
viability experiment by sonicating nZnO in autoclaved DI water at a concentration of
4.07 mg/mL for 10 min. RPMI 1640 without HEPES was then added to the stock solution
(to avoid vehicle eﬀects) to bring the ﬁnal concentration to 2.035 mg/mL and
subsequently sonicated for an additional 10 min. During the sonication step, cells were
concurrently plated and then treated with the nZnO stock solution immediately after
sonication. Cells were then cultured for 24 h at 37°C and 5% CO2. For the Alamar Blue
metabolic assay, Alamar Blue (10% (v/v)) was added 20 h after treatment with NPs and
incubated for an additional 4 h at 37 °C and 5% CO2. The ﬂuorescence intensity was
determined at 24 h by a Biotek Synergy MX plate reader using excitation/emission at
530/590 nm. Flow cytometry was also employed to verify experimental results. After the
24 h treatment period, cells were washed with PBS (phosphate buﬀered saline) and
resuspended in FACS buﬀer (PBS/15% FBS/0.02% NaN3) and stained with a FITC
labeled anti-HLA ABC antibody (BD Biosciences, San Jose, CA). Cells were
subsequently washed, and 0.4 μg/mL propidium iodide (PI) was added to stain and detect
nonviable cells using a BD FACS Caliber ﬂow cytometer.
Confocal Microscopy
Confocal microscopy was utilized in reﬂection mode to image the dissolution of
nZnO. Brieﬂy, 81.4 μg/ mL solutions of nZnO in nanopure water were placed on Wilco
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well glass bottom dishes and allowed to dry overnight. Nanopure water was added prior
to imaging as a control to ensure the disappearance of NPs was due to dissolution from
HEPES and not from solubility/ dissolution in water. Confocal images were acquired in
reﬂectance mode as a Z-stack/time series utilizing the α-Plan-FLUAR 100x/NA 1.45/oil
objective, an argon (514 nm) laser as excitation source, and a BP505−550 emission ﬁlter.
Speciﬁcally, images with a frame size of 69.1 μm × 69.1 μm (0.14 μm pixel size) were
acquired every 9.576 s for 30 min. To account for optical drift and ensure collecting the
optical plane of interest, three 0.2 μm overlapping slices over a Z-range of 0.4 μm were
collected. Image processing was performed with ZEN 2009 imaging software (Carl Zeiss,
Inc., Thornwood, NY).
Statistical Analysis
The data for Figure 2.9 were analyzed with a linear mixed model, with ﬁxed
eﬀects of presence or absence of HEPES buﬀer, concentration, and their interaction. The
date of the experiment was modeled as a random eﬀect using compound symmetry for
the correlation among outcomes run on the same date. Viability at each concentration was
compared between HEPES and no HEPES, and comparisons were adjusted using the
Bonferroni step-up correction to control family wise type 1 error rate at 5%.36
Results
ZnO Nanoparticle Synthesis and Characterization
nZnO was synthesized by a wet chemical method using the forced hydrolysis of
zinc acetate solubilized in DEG.35 X-ray powder diﬀraction spectra showed the expected
hexagonal wurzite crystal structure with an average crystal size of 9.0 ± 2.3 nm. The
lattice parameters obtained from analysis were a = 3.253 and c = 5.215, and no other
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crystal phases were detected. TEM images in Figure 2.1 show large aggregates with a
size range of 50−600 nm made up of small individual ZnO crystals of an average size of
9.8 ± 1.7 nm, which is consistent with XRD analysis (see Supporting Information, Figure
S2.8). The high resolution TEM (HRTEM) image (Figure 2.1C) demonstrates that the
crystal lattice terminates at the boundary of the crystals, indicating no coatings or
amorphous phases are present on the surface. Dynamic light scattering and
electrophoretic measurements performed in nanopure water revealed an average
hydrodynamic size of 345 ± 13.6 nm and zeta potential of +35.7 mV. Additional
characterization information from FTIR spectra, X-ray photoelectron spectroscopy
(XPS), and dissolution kinetics are discussed in subsequent sections.

Figure 2.1
(a) Scale bar: 1 μm. Low magnification image shows large spherical
aggregates of ZnO with a size range of 50-600 nm. (b) Scale bar: 50 nm. Higher
magnification reveals aggregates are comprised of nZnO crystals with an average size
of 9.8 ± 1.7 nm. (c) Scale bar: 10 nm. High-resolution TEM image demonstrates
crystal lattice termination at the crystal boundary with no amorphous structures or
coatings.
Real-Time Dissolution Kinetics
Certain media components have been shown to interact with NPs by inﬂuencing
their interactions with cells due to protein corona formation, development of insoluble
precipitants, and altering dissolution equilibriums.29,32,37 By utilizing the newly proposed
methods, numerous media components were screened to assess their eﬀect on the
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dissolution properties of nZnO. Media components tested, such as glucose and various
salts, had little eﬀect on the dissolution properties in the time scale evaluated but did
aﬀect particle aggregation and sedimentation proﬁles as seen in previous reports (see
Supporting Information, Figure S2.4).28,38 Interestingly, it was found that 4-(2hydroxyethyl)-1piperazineethanesulfonic acid (HEPES), a common component in
biological media, induces rapid dissolution of nZnO observed by UV/vis spectroscopy,
ﬂuorescence spectroscopy, and veriﬁed by ICP-MS (Figure 2.2). With this ﬁnding,
multiple biologically relevant buﬀers developed by Good et al. were tested.39 Many of
these buﬀers have been used in studies of nZnO in cell culture experiments, cellular
imaging, and to maintain physiological pH.25,27,29,35
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Figure 2.2
(a)-(f) Real-time dissolution kinetics of 40.7 μg/mL(0.5 mM) nZnO
from UV/vis spectroscopy and spectrofluorometric monitoring in various buffers
developed by Good et al. Each buffer was prepared at a stock concentration of 500
mM and was adjusted to pH=7.4. ICP-MS data points are plotted on the kinetics
profiles to demonstrate the reliability of converting spectra to quantitative
concentration measurements. Measurements reveal that each of Good’s buffers tested
(10 mM final concentration) induced rapid dissolution of nZnO within 20 minutes.
The real-time dissolution kinetics of 40.7 μg/mL nZnO (highest concentration
possible for linear correlation; see Supporting Information, Figure S2.3) is shown in
Figure 2.2 and demonstrates that all the buﬀers tested (pH = 7.4) induced rapid
dissolution with various kinetics proﬁles. The dissolution kinetics for both absorbance
and ﬂuorescence monitoring techniques is very consistent as seen in Figure 2.2, and all
experiments were performed in triplicate to ensure reproducibility (Supporting
Information, Figure S2.6).
To assess the accuracy and reliability of converting the absorbance and
ﬂuorescence spectra to nZnO concentration, ICP-MS was utilized. The same reactions
were completed in Ultracel-4 3k centrifugal ﬁlter units (pore size 0.1 nm) and centrifuged
at 4000g to separate the remaining NPs from the free zinc ions. The data points were
plotted over the kinetics proﬁles, which conﬁrmed the results obtained from the new
methods by utilizing absorbance and ﬂuorescence spectra (Figure 2.2).
At least 72.5% dissolution of 0.5 mM nZnO (40.7 μg/mL) was achieved from
each of the buﬀers (10 mM; pH = 7.4 ± 0.05) within 20 min (Table 1). The kinetics
proﬁles highlight the ability of these methods to monitor rapid real-time dissolution
kinetics that is lost in other quantitative assessments such as ICP-MS. Additionally, these
methods eliminate the need to separate the particles from the solution, reducing time and
cost factors. The ability to rapidly screen how biologically and environmental relevant
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species impact the dissolution of nZnO will facilitate characterization and toxicity
assessments.
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Table 2.1
ICP-MS measurements of the dissolution of nZnO (40.7 μg/mL) in
various solutions after 20 minutes. PBS and sodium bicarbonate appear to have a
lower percentage of dissolved nZnO than in nanopure water. However, insoluble zinc
phosphates and zinc carbonates are removed in the separation process, lowering the
calculated dissolution percentage. All of Good’s buffers tested (pH= 7.4) induced
72.5% or more dissolution within the 20 minute time frame.

Buffer/Media

Concentration

nZnO Dissolution %

Nanopure Water

-

4.8 ± 0.5

Phosphate Buffered Saline

1x

3.3 ± 0.3

Sodium Bicarbonate

1.5 mg/mL

1.4 ± 0.2

MOPS

10 mM

72.5 ± 0.2

TES

10 mM

72.8 ± 8.8

HEPES

10 mM

73.5 ± 6.4

BES

10 mM

82.4 ± 10.5

PIPES

10 mM

85.7 ± 1.5

Tricine

10 mM

99.6 ± 5.8

DLS was subsequently employed to qualitatively assess and conﬁrm the
dissolution of nZnO by monitoring the derived counts per second (CPS) while taking
measurements in size mode. As seen in Figure 2.3, the number of CPS drastically
reduced upon the addition of Good’s buﬀers, while the number of CPS in PBS was
maintained. In the solution containing tricine, the system stopped collecting
measurements due to insuﬃcient signal, qualitatively conﬁrming complete dissolution.
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Figure 2.3
A qualitative assessment of nZnO dissolution obtained from dynamic
light scattering (DLS) monitored in size mode. All six Good’s buffers induce rapid
dissolution of nZnO as demonstrated by the fast reduction in derived counts per
second (CPS).
Confocal microscopy was utilized to visualize the dissolution of nZnO induced by
the presence HEPES. No ﬂuorescent tags were used, and the images generated were due
to reﬂection from the NP aggregates on the bottom of the well. The apparent size of the
nZnO aggregates was consistent with TEM and DLS hydrodynamic size measurements.
As seen in Figure 2.4, little to no change was detected in the integrity of the NPs in water
over the ∼15 min (1000 s) time course. However, a striking reduction in size, intensity,
and sharpness of the NP was seen upon the addition of HEPES (Figure 2.4d−f). The vast
majority of NPs disappeared from the images within 250 s following the addition of
HEPES (see Supporting Information for time-lapsed video).
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Figure 2.4
Scale bar: 2 μm. A panel of nZnO confocal images obtained in
reflection mode as a time series/z-stack. (a)-(c) DI water was added as a control to
ensure any changes to the NPs wasn’t due to solubility in water. (d)- (f) HEPES
addition. nZnO quickly undergoes dissolution within the 250 second time frame,
demonstrating significant dissolution by HEPES.
Morphological Changes of ZnO NPs
It is important to note that the previous experiments were performed in simple
solutions without salts and additional buﬀers such as PBS. The dynamics of nZnO in
media are complex, and competing events such as protein corona formation, NP
agglomeration/sedimentation, and achieving dissolution equilibrium all impact the
toxicity proﬁles of nZnO. Additionally, reports have demonstrated microstructural
transformation of nZnO due to phosphate ions and have shown that free zinc ions react in
media to form various zinc carbonate and phosphate precipitants.29,31,40 The complex
nature of cellular media aﬀects the dissolution kinetics of nZnO and the results from the
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screening of numerous biological components prompted investigation into how inclusion
of HEPES could potentially alter the dynamics of nZnO in cellular media.
ICP-MS was used to quantify the amount of free zinc in the media to determine
any diﬀerences in dissolution kinetics from the inclusion of HEPES. nZnO was added to
RPMI 1640 (with and without 10 mM HEPES) in culture ﬂasks and placed in a cell
culture incubator to mimic viability assay conditions. As seen in Figure 2.5, the media
containing HEPES showed consistently higher levels of free zinc up to the 24 h time
point. However, at 24 h, the levels were not appreciably diﬀerent. This suggests a more
rapid initial dissolution of the NPs in the presence of HEPES that eventually reaches the
same equilibrium regardless of media composition. Since the inclusion of HEPES in
RPMI media increases the dissolution rate of nZnO, investigations into how HEPES
alters the structural transformation of nZnO were performed.

Figure 2.5
ICP-MS measurements on the amount of free zinc ions from nZnO
present in RPMI 1640 media with and without 10 mM HEPES over 24 hours.
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XRD was employed to assess changes in the nZnO crystalline size and to
determine if crystalline phases of zinc phosphate or zinc carbonate appear in the spectra.
In media with and without HEPES, only the hexagonal wurzite crystalline phase of ZnO
was detected over the 24 h time course (see Supporting Information, Figure S2.8).
However, any amorphous species formed in solution would not display a well-deﬁned
Bragg peak but broadening of the ZnO peaks were observed. During the 24 h treatment,
the apparent average crystalline size from XRD slowly reduced from ∼9.3 nm to ∼7.5
nm in both situations, but no apparent diﬀerences were noted between the samples from
XRD analysis.
We have previously demonstrated that nZnO with very similar properties such as
crystal size, lattice parameters, and band gap have signiﬁcant diﬀerences in their
hydrodynamic size, zeta potential, and cytotoxicity due to diﬀerences in their surface
chemistry.17 FT-IR was utilized to investigate how the surface chemistry changed and
determine which species formed. The FT-IR spectra of as-prepared nZnO showed the
characteristic Zn−O vibrational modes at 478 cm−1 (Figure 2.6).17,41 However, during the
24 h time course, the Zn−O peak shifts down to 455 cm−1, likely due to changes in the
surface structure inﬂuencing the Zn−O bonds in the NPs. The two peaks at 1411 and
1597 cm−1 are attributed to surface bound carboxylate groups retained from the zinc
acetate precursor or the DEG solvent.17 The intensity of these peaks was reduced upon
addition to RPMI 1640 media and new functional groups appeared in the spectra as early
as the 2 h time point.
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Figure 2.6
FTIR spectra of as-prepared nZnO and nZnO post incubation in RPMI
1640 with (right) and without (left) 10 mM HEPES over 24 hours. The as-prepared
nZnO FTIR spectra show a strong peak at 478 cm-1 indicative of the Zn-O modes.
Other functional groups found at 1411 cm-1 and 1597 cm-1 are due to carboxylate
groups retained from the zinc acetate precursor or DEG solvent. New functional
groups appear upon incubation in cellular media and the peaks at 550, 630 and 1050
cm-1 are attributed to PO43- stretching and bending modes. The peaks near 1535 cm-1
are from C=O stretching and may be from either carbonate formation or from Amide
II bonds from protein corona formation. The broad O-H region shifts from 3425 cm1 to 3338 cm-1 due to convolution of the O-H ban and new N-H stretching groups.
The emergence of the strong peak at 1050 cm−1 is attributed to a convolution of
the PO43− symmetric and antisymmetric stretching modes.42,43 The shoulder appearing at
550 cm−1 is a convolution of the Zn−O stretch and a bending mode of PO43−.44 The
shoulder appearing at 630 cm−1 is associated with the bending mode of PO43− and
increased in intensity over the 24 h.44,45 The peak centered at 1535 cm−1 is due to C-O
stretching, indicating carbonates or amide II formation derived from interactions with
carbonate or proteins in the media.46−50 Up to the 24 h time point, nZnO shows a
continual increase in peak intensity in the phosphate and carbonate/amide II regions.
However, when the two samples at 24 h are compared (Figure 2.7), the ratio between the
area of the phosphate peaks (1050 cm−1) and the area of the Zn−O modes (420, 445, and
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485 cm−1) is higher in the media containing HEPES (4.13 vs 2.75), indicating increased
dissolution and conversion to zinc phosphate.51−55 Over the 24 h, the O−H broad region
peak increased and shifted from 3425 to 3338 cm−1, likely due to both the O−H region
and increasing concentration of the N− H stretching regions from amide A and B
bands.49,50 The additional peak at 1650 cm−1 is due to the presence of either crystalline
water or more likely, the amide I mode from bound serum proteins.42,43,50,56 These results
indicate that the species formed are a complex mixture of nZnO, retained proteins from
fetal bovine serum (FBS) in the media, and insoluble precipitate formation that is likely
an amorphous mixture of zinc phosphate and carbonate species.

Figure 2.7
(a) FTIR spectra of nZnO incubated in RPMI 1640 with (blue) and
without (red) 10 mM HEPES at the 24 hour time point. The peak at 455 cm-1 is
attributed to Zn-O modes and the broad peak at 1050 cm-1 is a convolution of PO43stretching modes. Qualitatively, the peak intensity in HEPES free media is stronger
in the Zn-O modes and weaker in the phosphate stretching modes than the media
containing HEPES. The deconvolution of the Zn-O modes in media containing
HEPES (c) and without (b) at 24 hours was used to compare the samples. The area of
the 1050 cm-1 phosphate peak was divided by the area of the three Zn-O peaks
(420,445, and 485 cm-1). A peak area ratio of 4.13 was obtained for nZnO incubated
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in media containing HEPES vs. a ratio of 2.75 in the media without HEPES. This
demonstrates a faster conversion of nZnO to zinc phosphate in RPMI 1640 containing
10 mM HEPES.
XPS was utilized to quantify atomic concentrations of each element present as
well as verify FT-IR results. By looking at the survey spectra of nZnO/precipitants
collected at 24 h (Figure 2.8a), the atomic concentrations reveal that a major contribution
to the amorphous species is an organic matrix likely from fetal bovine serum (FBS)
proteins in the media. Additionally, by looking at the ratio between the total phosphate
and zinc gives atomic ratios at 2.0 (10 mM HEPES media) versus 1.65 (HEPES free
media), which is very similar to results obtained from FTIR, indicating increased
phosphate formations in media containing 10 mM HEPES. High resolution core level
scans of the Zn 2p3/2 region demonstrate a single peak at 1021.8 eV in the as-prepared
nZnO sample (Figure 2.8b). Once introduced to media, new zinc species become
apparent, with a new peak observed with a chemical shift of +2.0 eV from the Zn−O peak
(Figure 2.8c) indicating Zn-PO43− bond formation (see Supporting Information, Figure
S2.10). These results conﬁrm complex formations of nZnO, proteins, and insoluble
phosphate/carbonate precipitants.
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Figure 2.8
XPS spectra of nZnO. (a) Survey scan of nZnO incubated in RPMI
1640 cellular media with and without 10 mM HEPES. Atomic concentrations of the
various elements present are similar in both media types, however, the phosphorus to
zinc ratio is different, with atomic concentration ratios of 2.0 (10 mM HEPES) and
1.65 (No HEPES). (b) The core level high resolution scan of the Zn2p3/2 region of asprepared nZnO demonstrates a single peak with a binding energy of 1021.8 eV. (c) A
high resolution core level scan of the Zn2p3/2 peak of nZnO incubated in cellular
media for 6 hours reveals similar new zinc species present in both cases, apparent by
the new peak appearing with a chemical shift of about 2 eV. XPS data verifies similar
changes in media types, with a modest difference in the amount of ZnO conversion to
new species.
TEM was utilized to compare the structural transformation of nZnO in both media
conditions and to evaluate the integrity of the crystal lattice, formation of particle
aggregates, as well as amorphous species. The high-resolution TEM image in Figure 2.1
demonstrates that the as-prepared nZnO crystal lattice terminates at the crystal boundary
with no amorphous species or coating present. In contrast, amorphous species are seen
when nZnO is exposed to cellular media with or without HEPES as early as the 2 h time
point (Figure 2.9). From our FTIR and XPS studies, the amorphous species formed in
both cases is a mixture of proteins, zinc phosphates, and carbonates. Interestingly, the
morphological formation of the amorphous species is radically diﬀerent due to the
exclusion of HEPES in RPMI media.
The samples incubated in media containing HEPES show rapid degradation of the
spherical aggregates, making the particles appear more porous. Over the 24 h period,
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particle integrity is lost (Figure 2.9), and pieces of aggregates are seen with amorphous
material spread throughout. The high resolution TEM images (see Supporting
Information, Figure S2.11) reveal individual ZnO crystals embedded within the
amorphous material. Lower magniﬁcation TEM images (Figure 2.9; additional ﬁgures in
Supporting Information, Figure S2.11) show pieces that have broken oﬀ from the
aggregates and formation of precipitates retaining aggregates/pieces with irregular
morphologies.

Figure 2.9
(a)- (f) Scale bars: 200 nm. (a)-(c) TEM images of nZnO in RPMI
containing HEPES. Over 24 hours, integrity of the particles is lost, with increasing
porosity and portions of nZnO aggregates breaking off and amorphous material
embedded in the particles (additional HRTEM images in supporting information).
(d)- (f) TEM images of nZnO in RPMI excluding HEPES. Porosity is seen to increase
over the 24 hours, however the proteins and amorphous zinc phosphate/carbonate
form a matrix around the aggregates binding numerous particles together instead of
embedding between the nZnO crystals in the aggregate.
Even though FT-IR and XPS demonstrated similar species composition in both
media conditions, the transformation of nZnO was very diﬀerent when HEPES was
omitted from the media. Similar structures were seen in both media compositions for
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individual nZnO aggregates, but large fractions of the samples had very diﬀerent
morphologies. Interestingly, instead of the rapid degradation of the aggregates seen in the
presence of HEPES, the absence of HEPES allows for the amorphous species to form a
matrix/corona around the particles (Figure 2.9). With many particles bound together, this
feature impacts their dispersion stability and rapidly settle out of solution. The porosity of
the particles increases over 24 h; however, it appears to be less dramatic when HEPES is
absent with more of the spherical nature of the aggregates retained. The high-resolution
TEM images (see Supporting Information, Figure S2.11) demonstrate a higher density of
nZnO nanocrystals in the aggregates, and the amorphous species coat the particles instead
of being randomly distributed throughout the interior of the aggregates.
Taken together, these results demonstrate that HEPES aﬀects the dissolution and
structural morphology of nZnO in complex media conditions. Inclusion of HEPES or any
of the Good’s buﬀers evaluated likely impacts particle characterization and toxicity
results and may therefore contribute to discrepancies in the literature regarding nZnO
toxicity. With this is mind, we investigated how inclusion of HEPES in RPMI media
impacts the cytotoxicity of nZnO.
Viability
The cytotoxic eﬀects of nZnO on Jurkat leukemic cells have been reported by
numerous groups and the source of toxicity attributed to both dissolution properties and
ROS generation.20,35,57 ROS generation may be inherent to nZnO from surface layer
defects such as oxygen vacancies and elevated ROS levels have been associated with
increased cytotoxicity in leukemic cell lines.22 Direct interactions of nZnO with the
mitochondrial membrane has also been shown to lead to increased ROS production.23
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Additionally, ROS can also be generated due to signiﬁcant release of zinc ions by
inducing mitochondrial membrane leakage and subsequent increases in intracellular
superoxide levels, or possibly as a byproduct of the cell death process itself.20
Dissolution-related cytotoxicity has been attributed to high extracellular free zinc
ion concentrations and rapid intracellular dissolution in low pH environments such as
endocytic vesicle fusion with lysosomes.10 Inclusion of HEPES causes an increase in the
dissolution rate of nZnO and alters the NP surface structure and morphology, all of which
could inﬂuence dispersion stability, zinc ion homeostasis, and ROS generation. With this
in mind, investigations were performed to understand what inﬂuence the inclusion of
HEPES has on the viability proﬁle of Jurkat leukemic cells when challenged with nZnO.
Cells were treated with nZnO for 24 h and viability determined using both ﬂow
cytometry and the Alamar Blue assay. Zinc chloride was used as a control to assess the
toxicity of free zinc in the media. The Alamar Blue assay assesses the viability of live
cells based on their ability to metabolically convert resazurin into a ﬂuorescent signal.
Signiﬁcant changes (p < 0.001) in viability were observed due to the exclusion of HEPES
from the media (Figure 2.10). This could be attributed to potentially three diﬀerent
characteristics: (i) a more rapid release of free zinc ions into the media when HEPES is
present, (ii) diﬀerences in surface structure/chemistry aﬀecting ROS production, and (iii)
increased sedimentation of the NPs when bound together by the complex matrix when
excluding HEPES. The toxicity proﬁle of the zinc chloride control was similar in trend to
cells treated with nZnO in RPMI/HEPES media. This suggests that the initially higher
free zinc concentration due to the inclusion of HEPES may be a signiﬁcant contributor to
the toxicity mechanism.
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Figure 2.10 nZnO toxicity on Jurkat leukemic cells at 24 hours. (Left) Alamar Blue
assay demonstrating a significant difference in the toxicity of nZnO in media
containing HEPES vs no HEPES. (Right) Flow cytometry analysis confirms
significant changes to the viability of Jurkat cells when challenged with nZnO. (**
indicates p< 0.001; * indicates p< 0.05).
To verify the experimental results, viability was also determined by the uptake of
propidium iodide (PI) using ﬂow cytometry. In contrast to the Alamar Blue assay, the
uptake of PI labels late apoptotic/necrotic cells by intercalating between DNA base pairs
when membrane integrity is lost; thus, analysis is based upon the number of dead cells in
the population. A signiﬁcant diﬀerence (p < 0.001 for 3 conc.; p < 0.05 for 1 conc.) in the
viability of Jurkat cells was observed between the two media types (Figure 2.10). The
zinc chloride control again had a similar toxicity proﬁle when compared to the media
containing HEPES; however, at higher concentrations, the zinc chloride appears more
toxic. Assuming dissolution is the key driver of toxicity, this is expected since the free
zinc concentration does not reach equilibrium in nZnO treated media until at least the 6 h
time point (Figure 2.5) and nZnO crystals are still detectable after the 24 h time course.
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Discussion
This paper demonstrates the ability to use simple, relatively fast, and costeﬀective methods to quantitatively evaluate real-time dissolution kinetics of nZnO in
aqueous solutions. These methods, using UV/vis or a spectroﬂuorometer, could
potentially be adapted for use in more complex situations such as in wastewater treatment
studies or screenings in other biologically relevant solutions. This work also highlights
that screening interactions in simple solutions can be expanded to more complex
situations, leading to a better fundamental understanding of how nZnO behaves in model
systems that may impact nZnO dissolution, structural transformation, dispersion, and
cytotoxicity proﬁle.
The dissolution of nZnO is regarded as a signiﬁcant source of cytotoxicity and a
more complete understanding how nonessential media components such as Good’s
buﬀers contribute to the dissolution kinetics may help in deciphering reports on nZnO
toxicity. Good’s buﬀers are used extensively in biological studies to maintain
physiological pH and have been reported to be used in characterizations studies such as in
imaging buﬀers. The high level of dissolution induced by these buﬀers may impact
results and evaluations at all levels of nZnO assessments, and the impact of utilizing
Good’s buﬀers as a buﬀering system needs to be considered prior to use.
The structural and chemical transformation of nZnO has been shown to be
inﬂuenced by the concentration of carbonates and phosphates in solution.29,31 Here we
demonstrate that excluding HEPES from the media signiﬁcantly alters these
transformations. From basic chemical assessments, it appeared that there were modest
changes in the dynamics of converting nZnO into zinc phosphate and zinc carbonate.
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However, the matrix formation that appeared in HEPES-free media suggests that even
though chemically similar, structural changes can be dramatic. These structural changes
potentially alter nZnO dispersion stability, causing signiﬁcant changes in their
sedimentation proﬁles. We have previously shown how dispersion stability can greatly
impact the cytotoxic proﬁle of nZnO.58 Understanding the transformation of nZnO in in
vitro model systems will help in further determinations on the toxicity of nZnO.
From these studies, we further demonstrated that the diﬀerence in the dissolution
kinetics and transformation have signiﬁcant impacts on nZnO toxicity proﬁle in Jurkat
leukemic cells. These studies highlight that the observed toxicity proﬁle of nZnO stems
from more than just the physicochemical properties of the NP. Nanoscale ZnO
interactions with the environment can signiﬁcantly alter their characteristics and
conﬂicting reports on their toxicity mechanism could potentially be due to the media
composition. For our future studies, we plan to investigate the use of phosphate free and
HEPES free Dulbecco’s modiﬁed Eagle medium in place of RPMI 1640 media for
toxicity assessments to avoid potential artifacts arising from the transformation of nZnO
from phosphate and increased dissolution observed from Good’s buﬀers.
In conclusion, we have shown that a relatively simple, fast, and cost-eﬀective
method for screening the dissolution of nZnO can lead to a more thorough understanding
of how nZnO behaves in complex conditions. These results also indicate the need for
authors to ensure they list all details of the buﬀering systems used in published studies on
nZnO due to the various media compositions required for various cell types and the wide
use of Good’s buﬀers in characterization studies such as imaging solutions.
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Figure S2.1 Spectrofluorometric data of nZnO. (left) Raman peaks associated with
water appear in the same region as the nZnO fluorescence peak when using a higher
wavelength as the excitation source. A 310 nm excitation was chosen to prevent
convolution of the nZnO fluorescence peak with the Raman peak. (right) The
fluorescence spectra of nZnO at various concentrations using a 310 nm excitation
source. The peak intensity at 368 nm was used to monitor nZnO dissolution and
convert counts per second (CPS) to concentration.
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Figure S2.2 UV/vis data of nZnO. Example absorbance spectra of nZnO for various
concentrations, demonstrating the max absorbance at 368 nm. The peak intensity
value at 368 nm was used to convert nZnO absorbance to concentration for
dissolution studies.

Figure S2.3 Plots of fluorescence (left) and absorbance (right) vs. concentration.
There is a high linear correlation between nZnO CPS/Abs. and concentration up to
500 μM (40.7 μg/mL), allowing simple conversion for real-time quantitative analysis
of nZnO dissolution.
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Figure S2.4 Screening of multiple media components at biologically relevant
concentrations (obtained from ATCC product data sheet for RPMI 1640 medium;
product # 30-2001) demonstrate high stability of nZnO (40.7 μg/mL) in various
solutions. The slow decrease in CPS for these solutions is likely due to sedimentation
of nZnO.

Figure S2.5 Rapid dissolution of nZnO (40.7 μg/mL) in 25 mM HEPES buffer.
Adding nZnO to the solution already containing HEPES (black) never achieved the
CPS expected for the concentration used. Switching the approach (red) by suspending
nZnO in solution and then adding the buffer shows the same kinetics profile but
retains the information lost during the time of addition. All subsequent experiments
suspended nZnO in solution first, then added buffer to retain all dissolution kinetics
information.
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Figure S2.6 Two examples of triplicated measurements of nZnO (40.7 μg/mL) in
Good’s buffers. CPS and Abs. were converted into concentration by using the linear
correlation in Figure S3. Triplicate of fluorescence and absorbance measurements are
plotted (n=6) for each buffer demonstrating both methods are highly reproducible,
consistent, and accurate. ICP-MS was utilized to confirm the accuracy of converting
spectra information to concentration.

Figure S2.7 Additional representative plots of nZnO (40.7 μg/mL) in nanopure
water, phosphate buffered saline (PBS) and sodium bicarbonate. nZnO is stable in
nanopure water over the 20 minute time course demonstrating kinetics is due to
interactions with the media components. Interestingly, in both PBS and sodium
bicarbonate, the apparent concentration of nZnO increased upon addition of the
buffer. This is likely due to formation of zinc phosphates and zinc carbonates
respectively, causing an increase in both absorbance and fluorescence measurements.
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Characterization

Figure S2.8 XRD spectra of nZnO (40.7 μg/mL) post incubation in RPMI 1640
cellular media at various time points. In both conditions (with and without 10 mM
HEPES) only the wurzite crystal phase of ZnO was detected over the 24 hour time
course. No peaks from zinc phosphate or zinc carbonate were detected, however in
both cases the calculated average crystal size reduced from ~9.3 nm to ~7.5 nm.

Figure S2.9 FTIR spectra of nZnO incubated in RPMI cellular media for 24 hours
and precipitate collected from 50mM ZnCl2 solution dispersed in phosphate buffered
saline (PBS) or sodium bicarbonate. The Zn-O modes at 455 cm-1 are not present in
the zinc carbonate/phosphate precipitant. Spectra of the controls confirms peak
positions in literature that attribute the 550, 630, and 1050 cm-1 peaks to PO43-
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bending/stretching modes, 1650 cm-1 to crystalline water and 1535 cm-1 to C=O
stretching from carbonate.

Figure S2.10 Core level XPS spectra of the Zn2p3/2 region. ZnCl2 solution was
dispersed in PBS (pH= 7.4) and the precipitate was collected via centrifugation and
subsequently dried for 24 hours. Peak deconvolution demonstrates two zinc species
with a chemical shift of ~2.0 eV attributed to Zn- PO43- and Zn-OH.
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Figure S2.11 HRTEM images of nZnO post incubation in RPMI 1640 with (a)-(c)
and without 10 mM HEPES (d)-(f). (a)-(c) scale bar: 5 nm; Images show pieces of
irregular shaped nZnO aggregates. Porosity of the aggregates increased and the
amorphous zinc phosphate/carbonates are spread throughout with individual nZnO
crystals embedded. Scale bars: 10 nm (d), 5 nm (e) and 20 nm (f). (d)-(f) nZnO images
show the amorphous precipitants forming a matrix on the exterior of the aggregates,
binding the particles together. The HRTEM images show the individual nZnO
crystals comprising the aggregates are more densely packed than in the media
containing HEPES (top row). It appears the slower dissolution rate in HEPES free
media causes the precipitants to form on the exterior of the aggregates instead of
causing loss of particle integrity, resulting in higher porosity and causing pieces of
aggregates to separate from the particle.
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Figure S2.12 Scale bars: 200 nm except (a) and (e) (100 nm). Additional images of
nZnO incubated in media with (a-c) and without (d-f) 10 mM HEPES at 2, 6 and 24
hours. (a)-(c) Irregular shaped precipitants are seen in media containing HEPES and
the spherical shape of the aggregates is lost over the time course. (d)-(f) Matrix
formation around the particles is seen when omitting HEPES from the media. Many
aggregates are bound together and particles appear to retain their spherical
morphology. This would impact the dispersion stability of the nanoparticles and
formation of precipitants (top row) may contribute to the overall toxicity profile of
nZnO in viability assessments.
Web Enhanced Object
(See materials and methods for experimental details) Confocal microscopy timelapsed video demonstrates the dissolution of nZnO upon the addition of HEPES. The first
part of the video shows nZnO in nanopure water as a control to ensure any changes to
nZnO wasn’t due to dissolution or solubility in water. Upon addition of HEPES, the
majority of nZnO disappears from view. Link:
http://pubs.acs.org/doi/suppl/10.1021/acs.chemrestox.7b00136/suppl_file/tx7b00136_si_
001.avi
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Abstract
Background: The insuﬃcient understanding of unintended biological impacts
from nanomaterials (NMs) represents a serious impediment to their use for scientiﬁc,
technological, and medical applications. While previous studies have focused on
understanding nanotoxicity eﬀects mostly resulting from cellular internalization, recent
work indicates that NMs may interfere with transmembrane transport mechanisms, hence
enabling contributions to nanotoxicity by aﬀecting key biological activities dependent on
transmembrane transport. In this line of inquiry, we investigated the eﬀects of charged
nanoparticles (NPs) on the transport properties of lysenin, a pore-forming toxin that
shares fundamental features with ion channels such as regulation and high transport rate.
Results: The macroscopic conductance of lysenin channels greatly diminished in
the presence of cationic ZnO NPs. The inhibitory eﬀects were asymmetrical relative to

70
the direction of the electric ﬁeld and addition site, suggesting electrostatic interactions
between ZnO NPs and a binding site. Similar changes in the macroscopic conductance
were observed when lysenin channels were reconstituted in neutral lipid membranes,
implicating protein-NP interactions as the major contributor to the reduced transport
capabilities. In contrast, no inhibitory eﬀects were observed in the presence of anionic S
nO2 NPs. Additionally, we demonstrate that inhibition of ion transport is not due to the
dissolution of ZnO NPs and subsequent interactions of zinc ions with lysenin channels.
Conclusion: We conclude that electrostatic interactions between positively
charged ZnO NPs and negative charges within the lysenin channels are responsible for
the inhibitory eﬀects on the transport of ions. These interactions point to a potential
mechanism of cytotoxicity, which may not require NP internalization.
Background
The rapid development of certain nanomaterials (NMs) has led to their extensive
use in many commercial applications including cosmetics, sporting goods, automotive
parts, and electronics,1-4 while many others are under intense investigation for scientific,
technological, and biomedical applications.5-9 The large surface area to volume ratio of
these materials yields novel physical and chemical properties that enable applications that
are unachievable using micron-sized bulk material of identical composition. The
scientific community has spent decades developing an understanding of NMs in order to
control their fundamental physical and chemical properties. However, early
investigations demonstrated that some of the same properties that make NMs attractive
for multiple applications may cause unintended hazardous interactions with biological
systems. Therefore, environmental and human exposure poses potentially significant
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risks,10 and this paradigm has led to intense investigations on the potential biological
impact of NMs.11, 12 While we have thus far attained a tremendous body of knowledge on
end-point effects such as cytotoxicity, neurotoxicity, genotoxicity and oxidative stress,1316

we lack a thorough understanding of the principles by which modulation of size,

charge, composition, dissolution levels and surface chemistry affect the interaction of
NMs with living cells.
ZnO nanoparticles (NPs) are considered to be one of the more toxic of the metal
oxide NMs.17, 18 Studies on ZnO NPs have demonstrated toxicity towards a large number
of cell lines and model organisms, however, the mechanism of cytotoxicity is still under
debate. Certain physicochemical properties, such as surface chemistry, dissolution
potential, and their intrinsic ability to produce reactive oxygen species (ROS) have a
strong impact on their cytotoxic effects.19-21 Several studies have demonstrated that
cytotoxicity stems from high dissolution rates, causing elevated levels of Zn2+ ions in
cellular media that eventually disrupt homeostasis and leads to cell death.22, 23 Other
groups have suggested that their intrinsic ability to produce ROS (which may arise from
surface defects, such as oxygen vacancies) is responsible for the high cytotoxic potential
of ZnO NPs.24, 25 In the same line, SnO2 NPs have been shown to inhibit kinetic growth
and cytotoxicity towards certain cell lines and organisms,18, 26, 27 while other publications
have demonstrated modest to no cytotoxic effects.28, 29 Similar to other NPs, the crystal
and hydrodynamic size of SnO2 NPs play an important role on their toxic effects, and
smaller sizes have been shown to correlate with increased toxicity.27
Our inability to correctly predict how physical and chemical properties relate to
toxicity stems from the fact that biological systems are elaborate and structurally and
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functionally interconnected, making it very difficult to isolate distinct interactions
responsible for cytotoxicity. Therefore, investigations utilizing a simplified model system
that mimics the structure and function of a biological assembly can be an important step
towards a more complete understanding of mechanisms of nanotoxicity. In these regards,
we address how the directional flow of ions across lipid membranes containing
specialized transmembrane ion transporters are affected by NPs. This work is motivated
by the tremendous biological relevance of ionic transport for any living cell, and by the
evidence that malfunctions of the mechanisms that control the transmembrane transport
may have catastrophic consequences for cell functionality.30
Among transmembrane transporters, voltage-regulated channels play key roles in
fundamental cellular processes such as creating and maintaining electrochemical
gradients, transmission of information, ion transport, signaling, and metabolism.31 A
salient feature of such transporters is the regulation of their activity by transmembrane
electric fields interacting with voltage-sensing domains present in the channel’s
structure.32 The presence of charged domains in different regions of protein channels
presents opportunities for electrostatic interactions with charged NPs, which may affect
the transmembrane transport and functionality of the host cells.
Given the large variety of ion transporters in the cell membrane, isolating a
particular one in a specific cell for relevant studies on transport modulation induced by
NPs is not an easy task. Moreover, reconstitution of a particular ionic transporter in an
artificial membrane system, although feasible, may require multiple, extensive and costly
preparation steps. A simplified system featuring fundamental characteristics of ion
channels may constitute an excellent model for investigating potential nanotoxicity
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effects originating from the disruption of transmembrane transport of ions. Therefore, we
propose a simplified model that explores the effects of charged NPs on the transport of
ions through lysenin channels inserted into an artificial bilayer lipid membrane (BLM).
Lysenin is a pore-forming protein extracted from the coelom of the earthworm E.
foetida, which self-assemble as a large conductance nonameric pore (~3 nm) in artificial
and natural lipid membranes containing sphingomyelin (SM).33-35 The recently
deciphered crystal structure indicates large charged domains present within the
channel,36, 37 thus presenting a strong potential for electrostatic interactions with charged
NPs. The physiological role of lysenin is still obscure but the cytolytic and hemolytic
activity is indicative of a pore-forming toxin.38 Nonetheless, its relevance for
nanotoxicity studies stem from several remarkable biophysical properties it shares with
ion channels. Unlike many other pore-forming toxins and similar to voltage-gated ion
channels, lysenin channels present asymmetrical voltage-induced gating.33, 39 They adopt
an open state at negative voltages, while positive voltages larger than ~+20 mV induce
gating and closing.39, 40 This salient feature is complimented by reversible ligand-induced
gating, manifested as conformational changes in the presence of low concentrations of
multivalent metal cations leading to channel closure.41, 42 Once the multivalent cations
bind and induce conformational changes, the channel adopts a sub-conducting or closed
state.41, 42 Another advantageous property of lysenin channels is that voltage and ligandgating properties can be easily discriminated. This is achieved by reconstituting the
channels in neutral lipid membranes which maintains the ligand-induced gating
mechanism but renders lysenin unresponsive to the applied voltage.41, 42 The high
transport rate of lysenin channels yield large ionic currents which facilitate data recording
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and analysis. Lastly, lysenin channels are easily reconstituted in artificial membrane
systems containing SM, are stable for extended time periods, and the monomer form of
the protein is commercially available.
Methods
Chemicals and Nanoparticles
Asolectine (Aso), cholesterol (Chol), SM (from Sigma-Aldrich) and diphytanoyl
phosphatidylcholine (DiPhytPC, from Avanti Polar Lipids) were purchased as powders
and dissolved in n-decane at a final concentration of 50 mg/mL. For the support
electrolyte, NaCl (Fisher Scientific) was dissolved in nanopure water at a final
concentration of 130 mM (if not otherwise indicated) and buffered with 20 mM 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) at pH = 7.2. ZnO and SnO2 NPs
were synthesized using wet chemical methods as previously described.43, 44 Briefly, for
ZnO NP samples, the precursor zinc acetate dihydrate (Zn[CH3CO2]2·2H2O) was
suspended in diethylene glycol. The solution was heated and nanopure water was added
when the solution reached 80⁰ C. The temperature was then brought to and held at 150⁰ C
for 90 minutes. The NPs were collected by centrifugation and subsequently washed with
ethanol. For SnO2 NPs, sodium stannate (Na2[Sn(OH)6]) and urea were used as
precursors with nanopure water as the solvent. The solution was heated to 90 ⁰C and held
for 90 minutes. The NPs were collected via centrifugation and subsequently washed with
nanopure water. Characterizations were performed using X-ray diffraction (XRD) (Figure
S1, Additional file 1), transmission electron microscopy (TEM) (Figure S2 and S3,
Additional file 1), zeta potential (ZP) measurements, dynamic light scattering (DLS)
(Figure S4, Additional file 1), X-ray photoelectron spectroscopy (XPS) (Figure S5,
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Additional file 1) and Fourier-transform infrared spectroscopy (FTIR) (Figure S6,
Additional file 1). XPS confirmed sample purity and atomic concentrations for
stoichiometric ratios. XRD was employed to ensure crystal phase purity and to obtain
average crystalline size for both samples. XRD confirmed the expected hexagonal
wurzite crystal structure for ZnO and cassiterite for SnO2. The average crystal size for
ZnO and SnO2 NPs was analyzed with Rietveld refinement using Materials Analysis
Using Diffraction (MAUD) software and estimated at 8.3 +/- 2 nm and 4.3 +/- 0.04 nm
respectively. A JEOL JEM-2100 HR analytical TEM was used to confirm spherical
morphology and average crystal sizes. FTIR spectra was collected using a Bruker Tensor
247 spectrometer and FTIR pellets were produced by first grinding 1.6 mg of each NP
sample with 0.200 g of spectroscopic grade KBr. The ground powder mixture was then
pressed with 8 tons of pressure for 3 minutes and pellets were analyzed after removing
the KBr background. Zeta potential and DLS measurements were performed, after
dispersing the powders in nanopure water at a concentration of 1 mg/mL, using a
Malvern Zetasizer NanoZS. ZnO NP clusters had an average hydrodynamic size (HDS)
of 276 nm and average ZP of +32mV, whereas SnO2 NP clusters average HDS was 176
nm with an average ZP of -42.0 mV.
Bilayer Lipid Membrane Setup
The experimental setup employed the use of a planar BLM chamber consisting of
two polytetrafluoroethylene (PTFE) reservoirs separated by a thin (~120μm) PTFE film
that had been pierced with an electric spark to create a circular hole of ~ 70 µm
diameter.45, 46 The reservoirs were filled with 1mL buffered electrolyte and connected via
two Ag/AgCl electrodes inserted in the solution to an Axopatch 200B amplifier
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(Molecular Devices). The amplified analog signal fed the DigiData 1440A digitizer
(Molecular Devices) which provided the digital signal for visualization, recording, and
further analysis. Continuous stirring of the solutions in the BLM chamber was assured by
a low-noise magnetic stirrer (Warner Instruments). All the experiments were performed
in voltage-clamp mode upon manual or automatic voltage stimulation. The signal
recorded during various voltage stimulations was further analyzed with ClampFit
10.6.2.2 (Molecular Devices) and Origin 8.5.1 (Origin Lab) software packages.
Experimental Procedure
Lipid membrane preparation was performed by “painting” the hole in the PTFE
film with small amounts of lipid mixtures composed of 4mg Aso or DiPhytPC, 2mg
Chol, and 2mg SM dissolved in ~400μL n-decane.46, 47 The successful creation of the
BLM was indicated by measuring the capacitance in response to an applied triangular
voltage stimulation, while achievement of a seal resistance larger than 1000 GΩ was
assessed by measuring the leakage current in response to a DC voltage stimulation (100
mV). Channel insertion was performed by adding the lysenin monomer (from SigmaAldrich, 0.3 nM final concentration) to the ground (cis) reservoir under continuous
stirring and at -60 mV bias potential applied to the trans (headstage) reservoir. The
application of a negative voltage was required to prevent the voltage-induced gating
which manifests at positive transmembrane potentials.33, 39, 40 After the insertion process
was completed, as indicated by a steady state value of the open current, an extensive
flushing of the cis reservoir with lysenin-free electrolyte was performed to remove the
bulk monomer and prevent additional insertions. To avoid potential changes in the
lysenin functionality originating in congestion effects,48 the total number of channels
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inserted into the membranes was limited to ~1000. To facilitate quantitative comparison
of the influence of NPs on the transport properties of lysenin channels in parallel
experiments comprising different numbers of inserted channels, we used the relative
changes in the macroscopic conductance (Gr = G/G0) for data plotting, where G is the
conductance after addition of NPs and G0 is the conductance before addition. In order to
avoid premature dissolution and/or aggregation, the NPs (powder form) were dispersed
by sonication for 5 minutes in the support electrolyte solution in a sonication bath before
each addition to the reservoirs.
Results and Discussion

Figure 3.1
The experimental setup comprises lysenin channels reconstituted into
planar lipid bilayer membranes. The modulation of ionic transport and regulation by
ZnO NPs is assessed in classic voltage-clamp experiments.
Once a steady state current through the population of lysenin channels was
achieved, the NPs were introduced into either side of the chamber with both negative and
positive voltages applied across the membrane to assess their effect on the macroscopic
conductance (see Fig. 1 for a schematic of the setup). The addition of ZnO NPs (20
µg/mL final concentration) to either side of the membrane containing lysenin channels,
when biased by -60 mV, yielded only a modest decrease of the macroscopic conductance,

78
i.e. a few percent, irrespective of the side of addition (Fig. 2). This slight decrease in the
conductance suggests a minimal influence of ZnO NPs on the lysenin channels’ ability to
transport ions in these particular experimental conditions.

Figure 3.2
ZnO NPs do not alter the ionic conductance of lysenin channels when
biased by a -60 mV transmembrane voltage. Addition of ZnO NPs to either trans (a)
or cis (b) reservoirs induces only negligible changes of the macroscopic conductance.
The experimental values are reported as mean ± S.D., n = 3. All the data points
represent experimental values but symbols have been skipped for improved visibility.
To explain the small reduction in conductance, one may hypothesize several
different mechanisms such as ligand gating induced by small amounts of Zn2+ ions
provided from low NP dissolution, ligand gating induced by NP binding to a specific
binding site, or physical occlusion by transient NP attachment to the opening of the
nanopore. Past investigations show a dramatic yet reversible decrease of the macroscopic
conductance of lysenin channels in the presence of low concentrations of multivalent
cations,41, 42 indicative of strong interactions with lysenin channels. Those interactions
have been elucidated in single-channel experiments, which provide evidence of gating,
i.e. transition from the open state to a sub-conducting or closed state.41, 42 To explain
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lysenin’s reversible gating in the presence of multivalent cations, it is assumed that the
channel’s structure contains at least one negatively-charged binding site with high
affinity for cations, which triggers gating upon binding. A potential leakage of Zn2+ ions
from NPs may affect the macroscopic conductance of lysenin channels, as observed. In
addition, if exposed this binding site could electrostatically interact with cationic NPs and
yield a significant decrease in conductance either by induced gating or physical occlusion
of the conducting pathway. However, such strong effects were not observed in the above
experimental conditions, which prompted us to look closer to the lysenin’s structure for
alternative explanations. The assembled lysenin channel shows the presence of multiple
anionic domains,36, 37, 49 hence presenting opportunities for physical occlusions of the
channels through electrostatic interactions even in the absence of gating. We may account
for the weak conductance inhibition by considering the position of a binding site and the
orientation of the external electric field. A deep-buried binding site would be inaccessible
from either side to NPs larger than the channel’s diameter (~3 nm), which is mostly the
case in our investigations. Nanoparticle interaction with a binding site present at the trans
opening of the channel would be prevented at -60 mV by the electric field orientation.
Although the electric field in the bulk is very low, its amplitude increases substantially
when approaching the channel opening (fringe effects), therefore keeping the NPs far
from a binding site located at the cis opening. The same electric field will drive the NPs
added to the cis side towards the membrane but the lack of changes in macroscopic
conductance suggest the absence of a binding site at this location. The hypothesis of an
exposed binding site at the trans opening was further sustained in similar experiment
comprising trans NP addition and no transmembrane voltage; in such experimental
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conditions, a marked decrease of the macroscopic conductance was observed at -60 mV
after two hours of NP incubation in the absence of a bias potential (data not shown).
However, this result could be an artifact originating from dissolution during the
prolonged NP exposure to the electrolyte solution.
To identify if the elusive binding site is located either deep within the channel or
at the trans side, we performed the experiments under positive bias potentials (Figure 3).
After the channel insertion process, the influence of ZnO NPs was assessed in
experiments comprising of cis or trans addition and opposite orientations of the electric
field. Lysenin channels are voltage-gated at positive voltages greater than ~+20 mV but
are stable in the open state for extended time periods as long as the applied voltage is less
than this critical value.33, 39 Interestingly, addition of ZnO NPs to the trans side under
positive biasing (+15 mV to prevent voltage gating) induced a rapid and sustained
decrease of the macroscopic conductance (Fig. 3), while cis addition elicited only a weak
response in otherwise similar conditions. Consequently, we concluded that the electric
field plays a major role in preventing ZnO NPs accumulation near the membrane when
biased by -60 mV, however, in the absence of an electric field or when positive voltages
are applied, ZnO NPs may interact with a binding site situated at the trans opening of the
channel.
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Figure 3.3
Interactions between lysenin channels and ZnO NPs at +15 mV bias
potential. Cis addition (green) of ZnO NPs yield minor changes in the macroscopic
conductance. In contrast, trans addition (blue) elicits a significant decrease of the
macroscopic conductance by ~70 %. The experimental values are reported as mean
± S.D., n = 3. All the data points represent experimental values but symbols have been
skipped for improved visibility.
Dissolution of ZnO NPs can result in high extracellular Zn2+ concentrations which
have been proposed as one of the main mechanisms of ZnO NPs cytotoxic effects.22, 23, 50
Zinc ions inhibit the macroscopic conductance of lysenin channels by a ligand-induced
gating mechanism.41, 42 Due to the high sensitivity of lysenin channels to Zn2+, dissolution
may explain the observed inhibition of conductance upon exposure to ZnO NPs. To
eliminate such potential experimental artifacts, we performed investigations in similar
conditions but added Zn2+ ions (ZnSO4; 2 mM final concentration) to the reservoirs
instead of ZnO NPs. Addition of Zn2+ to the either side, biased by -60 mV, yielded a
sudden decrease of the macroscopic conductance in agreement with previous reports (Fig.
4).41, 42 Addition of the same amount of Zn2+ to a similar BLM containing lysenin
channels and biased by +15 mV (to prevent voltage-induced gating) yielded a similar
relative decrease of the macroscopic open current (Fig. 4). If conductance inhibition
elicited by ZnO NPs had been induced by the Zn2+ ions dissipating from the NPs, then
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addition to either side would have displayed a similar pattern of conductance inhibition.
However, addition of Zn2+ ions yielded fundamentally different results compared with the
experiments involving ZnO NPs. Zn2+ ions affected the macroscopic conductance
irrespective of the side of addition and direction of the electric field, while the inhibitory
activity of ZnO NPs depended on both these experimental parameters. The total
concentration of ZnO NPs was only 20 μg/mL (corresponding to ~0.25 mM Zn2+ ions)
and resulted in a 70% decrease in the macroscopic conductance. In order to obtain an
approximate decrease of only 45% in conductance measurements with Zn2+ ions, the
experiment employed a final concentration of 2.0 mM. Assuming complete dissolution of
ZnO NPs, this would correlate to approximately eight times the amount of Zn2+ ions from
ZnSO4 in the solution. To further eliminate the possibility that the Zn2+ ions contributed
to the observed conductance inhibition, experiments with ZnO NPs were carried out in
the presence of the strong Zn2+ chelator EDTA. EDTA (10 mM) was added to the
solutions prior to nanoparticle addition, thus effectively preventing any interactions of the
free zinc ions from the NPs with lysenin channels. These experiments yielded almost
identical decreases in the macroscopic conductance when compared with ZnO NPs with
no EDTA (Figure S7, Additional file 1). Our results clearly indicate that the conductance
inhibition elicited by ZnO NPs was not a consequence of Zn2+ ions from dissolution.
These experiments revealed that the extent of the conductance inhibition depended on
both the orientation of the lysenin channels and the electric field relative to the site of
ZnO NP addition. The observed conductance inhibition may originate from local
accumulation of NPs by electrophoretic effects, specific interactions with the membrane
itself, or preferential interactions with binding sites of lysenin.
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Figure 3.4
Zn2+ ions decrease the macroscopic conductance of lysenin channels
irrespective of bias potential and site of addition. At +15 mV transmembrane voltage
(a), Zn2+ addition to either the cis or trans reservoir reduces the macroscopic
conductance by ~ 40%. Similar decreases are recorded upon Zn2+ interactions with
lysenin channels biased by -60 mV (b). The presented data represent a typical single
run for each experiment.
Next, we asked whether or not exposure to ZnO NPs changes the voltage-induced
gating profile. To answer this question, the voltage-induced gating of lysenin channels
was assessed from the I-V plot recorded in the range -60 to +60 mV (Fig. 5) at a voltage
rate of 0.2 mV/s with and without the addition of ZnO NPs. The macroscopic current
recorded in absence of NPs (Fig. 5) featured the well-known characteristics of voltageinduced gating, i.e. a linear behavior in the negative voltage range, indicative of the
absence of gating, and a non-linear behavior at positive voltages higher than +20 mV,
indicative of channel closure.33, 39, 40 A typical feature of the macroscopic current
recorded at positive voltages is the transition from high current to low current through a
dynamic negative resistance region.39, 40 The macroscopic currents recorded in the same
voltage range after addition of ZnO NPs (20 µg/mL final concentration) to the trans side
of the membrane yielded a fundamentally different I-V plot (Fig. 5). The addition of ZnO
NPs elicited a slight decrease in the open current recorded in the negative voltage range,

84
however, the I-V characteristic preserved quasi-linearity between -60 mV and -20 mV.
Once the voltage approached neutral values, the macroscopic current greatly deviated
from the control I-V plot and the ionic transport capabilities of lysenin channels were
strongly diminished in the presence of ZnO NPs. Interestingly, the macroscopic
conductance started to decrease at small negative voltages, as indicated by the diminished
slope of the I-V plot. This is consistent with the hypothesis that the fringe effect of the
electric field prevents the NPs from interacting with the binding site. The magnitude of
the electric field decreases with decreasing applied voltage and the weak electrophoretic
force, although opposed, is not sufficient to prevent interactions with the binding site and
channel conductance modulation. The consistently lower macroscopic currents indicated
that addition of ZnO NPs induced severe channel conductance inhibition as demonstrated
by the large decrease of the macroscopic current at any positive voltage. At positive
voltages, the currents recorded in the presence of ZnO NPs were consistently lower than
the currents recorded in the absence of ZnO NPs up to ~+40 mV, after which the
recorded currents were similar to the control when the channels are in a closed state.
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Figure 3.5
Effects of ZnO NPs on lysenin voltage-induced gating. In the absence
of NPs, lysenin channels begin to close at transmembrane potentials greater than 20
mV (green curve). ZnO NPs (20 µg/mL final concentration) almost completely
abrogate the conductance in the positive voltage range (blue curve) and indicate a
strong interaction with the lysenin channels. All points on the curves are experimental
data and symbols have been added for discrimination. The presented data represent
a typical single run for each experiment.

This experiment demonstrated that ZnO NPs affect the macroscopic conductance
of lysenin channels in a voltage-dependent manner but it does not offer a complete
mechanistic description. The significant changes in the I-V curve after addition of ZnO
NPs potentially stem from multiple mechanisms. Experimental evidence and theoretical
modeling have demonstrated that electrostatic interactions between membrane
components and NPs are key factors that contribute to toxicity and the ability of NPs to
internalize into cells.51-53 Our experiments comprised a simple system consisting of
lysenin channels inserted into an artificial BLM composed of charged lipids. We assumed
that the conductance of lysenin channels was affected by interactions between the
proteins channels and NPs but we could not exclude interactions between the charged
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lipids and ZnO NPs as a source of conductance modulation. The Aso lipid mixture used
for BLM preparation contains several anionic components that may interact
electrostatically with voluminous cationic NPs unable to penetrate the lumen, which
would lead to channel conductance modulation. To elucidate the potential role played by
the charged lipids, we performed experiments by replacing Aso with neutral DiPhytPC.
The use of neutral lipids abolishes the voltage-induced gating at positive voltages while
preserving the ligand-induced gating observed in the presence of multivalent cations.41, 42
Addition of ZnO NPs to the cis side of a neutral membrane containing lysenin channels
and biased by +60 mV elicited no change in the macroscopic conductance (Fig. 6).
However, addition of ZnO NPs to the trans side of the same membrane, biased by an
identical positive voltage, yielded a massive decrease in conductance similar to the
results obtained using charged lipids (Fig. 6). The non-symmetrical response and
preservation of the inhibitory capabilities of ZnO NPs recorded for the neutral BLM
suggest that the inhibition mechanism excludes electrostatic interactions between NPs
and lipids. The interaction between lysenin channels and ZnO NPs is therefore likely
responsible for the observed inhibitory activity.
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Figure 3.6
Lysenin channels reconstituted in neutral lipid membranes interact
with ZnO NPs at +60 mV transmembrane voltage. Cis addition of ZnO NPs elicits no
changes in the macroscopic conductance. In contrast, ZnO NPs added to the trans
reservoir interact with lysenin channels and significantly diminish their ionic
transport capabilities. The experimental values are reported as mean ± S.D., n = 3.
All the data points represent experimental values but symbols have been skipped for
improved visibility.
We have shown that lysenin channels interact with positively charged ZnO NPs
but have not yet demonstrated the electrostatic nature of those interactions. Therefore, we
asked whether or not any NPs electrophoretically driven towards a specific or nonspecific yet accessible binding site would interact with lysenin channels and inhibit their
conductance. In this respect, we performed conductance experiments by replacing
positively charged ZnO NPs with negatively charged SnO2 NPs (-42 mV ZP).
Irrespective of the applied voltage and the addition site, SnO2 NPs did not affect the
macroscopic conductance of lysenin channels (Fig. 7). In order to try to elicit interactions
with SnO2 NPs, 200 μg/mL (final concentration) of SnO2 NPs were used, which is 10x
the concentration of ZnO NPs that induced rapid decreases in the macroscopic
conductance (Fig. 3). The crystal and hydrodynamic sizes of SnO2 NPs used in this
experiment were much smaller than ZnO NPs, suggesting that SnO2 NPs would be better
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suited to inhibit conductance by physical occlusion. The absolute magnitude of the ZP for
SnO2 NPs was also larger than ZnO NPs, further strengthening the hypothesis of a
mechanism that requires strong electrostatic interactions between cationic ZnO NPs and
an anionic domain present at the trans side of the lysenin channel to induce conductance
inhibition. Also, to further support the hypothesis that electrostatic interactions between
the lysenin channels and ZnO NPs initiate a decrease in conductance, we investigated the
effects of electrostatic screening induced by an increased ion concentration in the bulk
electrolyte solutions. Addition of 20 µg/mL ZnO NPs to the trans side of the bilayer
containing lysenin channels in 500 mM NaCl and under positive bias reduced the
conductance inhibition by ~15% (Figure S8, Additional file 1), which is a large reduction
from what we observed at 130 mM NaCl concentration (~70%, Fig. 2). In addition, the
time required to reach equilibrium increased to more than 2500 s, indicating that ionic
screening weakened the interactions between NPs and lysenin channels, and supporting
the hypothesis that electrostatic interactions are at the origin of the observed changes in
conductance. However, we may not eliminate potential artifacts arising from the effects
of screening on the ZnO NPs. At high salt concentration, screening may accelerate NP
aggregation, which is what we observed when attempting to further increase the ionic
concentration of the bulk electrolyte solutions. The ZnO NPs rapidly aggregated into
large clusters at the bottom of the vials in a matter of minutes, which prevented further
experimentation in high ionic strength conditions.
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Figure 3.7
Interactions between anionic SnO2 NPs and lysenin channels
reconstituted into a planar bilayer lipid membrane. Addition of SnO2 NPs to the trans
reservoir at -60 mV (a) and +15 mV (b) indicates insignificant changes of the
macroscopic conductance. Similarly, SnO2 NP addition to the cis reservoir at -60 mV
(c) and +15 mV (d) yields negligible changes in the ionic transport capabilities. The
presented data represent a typical single run for each experiment.
A few assumptions can be proposed about the mechanism responsible for the
observed decrease in macroscopic conductance elicited by addition of ZnO NPs.
Electrostatic interactions may bring ZnO NPs close enough to the channels such that the
resulting physical blockage reduces the individual currents. In such case, an opposite
electric field of appropriate magnitude may drive the NPs away from the binding site
therefore unblocking the channels. Our attempts to apply higher voltages across the BLM
and to force the unblocking were not successful. However, it is possible for the binding
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site to have a relatively strong affinity for charged ZnO NPs and consequently the force
required to remove the NPs from the binding sight may require much higher electric
fields. Unfortunately, such experiments are very difficult to achieve as the BLM is prone
to disruption at high transmembrane voltages.
Another potential inhibition mechanism mimics ligand-induced gating. It has been
established that lysenin channels interact with multivalent cations and undergo
conformational transitions that force the channel into closed or sub-conducting states.41, 42
This ligand-induced gating mechanism relies on electrostatic interactions between cations
and one or more binding sites but ionic current blockage stems from the induced gating.
It is possible that charged ZnO NPs interact electrostatically with one or more binding
sites, yet not necessarily the same one(s) involved in the ligand-induced gating and would
force the channels to adopt a sub-conducting or a closed state. Lastly, defects on the
surface of ZnO NPs such as oxygen vacancies have been shown to correlate with ROS
production.24, 54 Since the electrostatic interactions induce close contact of ZnO NPs with
the channels, the highly reactive surface of ZnO NPs may interact with cysteine and
methionine residues in their structure which may alter channel functionality and
conduction similar to reports of oxidation of cysteine residues in Ca2+/K+ channels.55, 56
Conclusions
Our work demonstrates that the transport properties of lysenin channels change
significantly in the presence of cationic ZnO NPs. The modulation of the transport
properties by NPs is strongly dependent on the net charge, and the orientation of the
electric field and channel with respect to the NPs. There is little doubt that the primary
interaction between NPs and lysenin channels is electrostatic. Nonetheless, the simplicity
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of the experimental system investigated here does not necessarily warrant biological
interpolation to other protein channels interacting with NPs, not even ZnO. In complex
biological environments, the binding of various functional groups on the NP surface may
significantly alter their ability to interact with membrane components irrespective of the
surface charge of the pristine nanomaterial. Given the aggregation tendency of the
investigated NPs, we may not exclude aggregation at the membrane surface as being at
the origin of conductance changes. Even the neutral lipids used for our investigations
present a dipole moment that may initiate NP binding; further NP aggregation at these
binding sites may impede the ionic flow by physical occlusion or by introducing
supplementary electrostatic energy barriers for ions. However, if an induced dipole
moment that initiated binding of NPs to lipids occurred, then SnO2 NPs should have
yielded a similar response due to their higher net charge. In spite of these shortcomings,
an important conclusion of this report pertains to the potential ability of NPs to interact
with transmembrane transporters without the need of internalization. Many previous
studies assume that cytotoxic effects of NPs are due to translocation of NPs into the
cytosol by various transport mechanisms and/or dissolution of the NPs, disrupting
homeostasis and interfering with vital cellular processes. Our work suggests that NPs
may tamper with ionic transport mechanisms by basic electrostatic interactions. Given the
physiological relevance of controlled transmembrane transport, such alterations may have
catastrophic effects for cells. While this observation is generally valid for any cell, it may
prove extremely helpful for understanding the potential neuro-toxic effects of NPs.57 The
physiology of the neural cell is based on the transport properties and regulation of
voltage-gated ion channels, which are transmembrane structures with multiple charged
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domains that may interact electrostatically with NPs. Changes in the voltage-induced
gating mechanism or blockage of ionic transport induced by NPs57 may dramatically
affect the correct functionality of the nerve cell. Such interactions may explain why
certain NPs specifically alter the individual currents through specific channels while the
transport properties of other channels are not affected by various NPs.58, 59 The local
distribution of charge within the structure of several ion channels is currently known so it
may be possible to predict potential toxic effects based on interactions with charged NPs,
or to design NPs intended to alter the activity of transmembrane transporters.
This foray into deciphering the effects of NPs on the transmembrane transport of
ions indicates alterations in the transporters’ functionality as a potential mechanism of
cytotoxicity. A previous study shows that ZnO NPs may induce neuronal cytotoxicity and
genotoxicity in the absence of internalization or free Zn2+ ions released from the NPs.60
Future experiments will shed more light on intimate mechanistic details and the role that
electrostatic interactions play in modulating the biological activity of protein channels.
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Figure S3.1 The XRD spectra of ZnO (left) and SnO2 (right). For ZnO, XRD
confirmed the hexagonal wurzite crystal structure with no alternate crystal phases
detected. The average crystal size determined for ZnO was estimated at 8.3 nm. The
XRD spectra of SnO2 demonstrated the crystal phase obtained was cassiterite with no
alternate phases present. The average crystal size for SnO2 was determined to be 4.3
nm from the XRD spectra.

Figure S3.2 TEM images and electron diffraction pattern of ZnO nanoparticles.
(Left; scale bar: 100 nm ) The lower magnification image shows that the ZnO crystals
aggregate to form larger spheres. (Middle; scale bar: 5 nm) Higher magnification
images demonstrate that the large aggregates are comprised of small ZnO
nanoparticles with an average size of ~10 nm. (Right; scale bar: 5 1/nm ) The electron
diffraction pattern obtained from the ZnO nanoparticle sample.
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Figure S3.3 TEM images and electron diffraction pattern of SnO2 nanoparticles.
(Left; scale bar: 100 nm ) The lower magnification image shows that SnO2
nanoparticles also form larger aggregates which are generally smaller than the
aggregates seen from the ZnO nanoparticles used. (Middle; scale bar: 5 nm) Higher
magnification reveals that the aggregates formed are from small SnO 2 nanoparticles
with an average size of ~5 nm. (Right; scale bar: 2 1/nm ) The electron diffraction
pattern obtained from the SnO2 nanoparticle sample.

Figure S3.4 Hydrodynamic size distributions of ZnO (left) and SnO2 (right)
obtained from dynamic light scattering measurements. Hydrodynamic size
distributions of SnO2 demonstrate smaller average aggregates than ZnO, consistent
with images obtained from TEM. The smaller particle size of SnO2 suggests that these
NPs would be better suited to inhibit conductance of lysenin channels by physical
occlusion but this was not observed experimentally.
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Figure S3.5 X-ray photoelectron spectroscopy survey spectra of ZnO (left) and
SnO2 (right) nanoparticles. Spectra demonstrate high sample purity, small retention
of carbon species and sodium in the case of SnO2, likely from carbon dioxide from
atmospheric exposure and species retained from the chemical precursors.

Figure S3.6 Fourier-transform infrared (FTIR) spectra of ZnO (left) and SnO2
(right) nanoparticles. Spectra confirm retained species from chemical precursors and
carbon dioxide, as well as demonstrate hydroxide species are present in both
nanoparticles synthesized.
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Figure S3.7 Interactions between ZnO nanoparticles and lysenin channels with
EDTA (10 mM) present in the solution reservoirs. EDTA is a strong chelator of Zn 2+
ions and thus prevents interactions between lysenin nanochannels and zinc ions.
Nevertheless, ZnO nanoparticles elicited a strong conductance inhibition of lysenin
channels, even with EDTA present, clearly demonstrating that inhibition is due to
interactions between ZnO and lysenin, not free zinc ions.

Figure S3.8 Ionic conductance of lysenin channels in the presence of ZnO
nanoparticles while using a significantly higher electrolyte concentration in solution
(500 mM). When compared with experiments under low electrolyte solutions (130
mM), the ZnO nanoparticles elicited a much weaker response. The reduction in
conductance inhibition may be due to: 1) Debye screening effects that reduce the
electrostatic interactions between ZnO nanoparticles and lysenin channels,
preventing the initial binding event required for conductance inhibition and 2)
increased aggregation of ZnO nanoparticles, which reduces interactions between
lysenin channels and ZnO nanoparticles.
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Abstract
Many attributes of ZnO nanoparticles (nZnO) have led to their utilization in
numerous electronic devices and biomedical technologies. nZnO fabrication methods can
create a number of intrinsic defects that modulate their properties and can be exploited
for the intended purpose. Here we developed a procedure to control the defects states of
pure nZnO that are theorized to contribute to the n-type conductivity of the material.
These defects reduced the nanoparticle (NP) band gap to ~3.1 eV and generated strong
emissions in the violet to blue region while also minimizing the defects responsible for
the more common broad green emissions. Several characterization techniques including
TGA, FT-IR, XPS, TEM, Raman, photoluminescence and ICP-MS were employed to
verify the sample purity, assess how modifications in the synthesis procedure affect the
various defects states and understand how these alterations impact the physical
properties. The changes to the physical properties prompted investigations into using
these NPs for bio-imaging purposes. We demonstrate the ability to utilize traditional
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fluorescence microscopy techniques to excite the nZnO with a 405 nm laser and detect
their emissions during live-cell imaging experiments. This work lays the foundation for
the use of these NPs in various bio-imaging and potential optoelectronic applications.
Introduction
Nanomaterials composed of ZnO are highly produced and extensively studied due
to their promising attributes in numerous fields. ZnO nanomaterials (NMs) are considered
for various potential cancer treatment options, water treatment applications and electronic
devices.1-3 The flexible nature of NMs, specifically the ability to control physical
properties such as size, surface chemistry, catalytic activity and defect structure, makes
them suitable for many novel devices. Researchers often focus on how these properties
relate to ZnO nanoparticle (nZnO) toxicity; especially as they appear to be selectively
toxic towards cancer cells when compared to their normal non-transformed counterparts.4 Although there has been a wealth of data collected about nZnO properties and
toxicity, the mechanism of toxicity and cell selectivity remains controversial as it is not
fully understood. The ability to fluorescently track nZnO within biological systems is an
avenue that should be further explored as it would likely facilitate a better understanding
of nZnO interactions with various cell types and cancer.
Numerous semiconducting nanoparticles (NPs) have generated great interest as
biological labels due to their small size, photo-stability and relatively long fluorescence
lifetimes.5, 6 The most traditional systems use cadmium chalcogenides as their emission is
tunable through size modulation and generally have narrow emission spectra.
Unfortunately these particles are toxic towards biological systems through the release of
Cd2+ ions; reportedly highly toxic in the nanomolar range.7 In contrast, nZnO display
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relatively low toxicity, at an even higher micro-to-millimolar range.8,9 As nZnO are
comparatively less toxic, their potential use in bio-imaging has received considerable
attention and yet only modest progress has been made to date.
Using nZnO as a biological labelling tool is partially limited by the need to use
UV excitation sources coupled with corresponding emission spectra of nZnO that
consists of two peaks; one generally in the UV range (correlating to near band emissions
of ~3.37 eV or ~368 nm) and one with the commonly reported broad green emission
(~500-700 nm). True UV excitation sources (100 nm-380 nm) are generally absent in
conventional fluorescence imaging instruments with most traditional fluorescence
microscopy techniques using excitation wavelengths of 405 nm or longer, which is
insufficient to excite nZnO as it is below the band gap energy of ZnO. Monitoring UV
emissions with standard fluorescent imaging equipment is often not possible, which
limits the ability to study nZnO in biological systems. Additionally, the broad green
emission of nZnO is theorized to originate from surface defects, such as oxygen
vacancies, that can be quickly quenched by transformations in solution such as hydroxide
formations and conversion to zinc carbonate/phosphate species.10-12 An additional
complication to targeting the broad green emission region for fluorescence microscopy
techniques is that emissions in this region of the spectrum is broad enough to overlap
with other fluorophores commonly used in cell and tissue research. Therefore, targeting
the broad green emission spectra of nZnO for imaging purposes may not be suitable for
many applications.
Some of the aforementioned drawbacks have been overcome through
modifications of nZnO, creating novel fluorescent particles through methods such as
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encapsulating dyes including fluorescein isothiocyanate (FITC), coating nanoparticles
(NPs) with polymers, and doping elements into nZnO to modulate the band gap.13-15
However, these modifications may impact other properties of nZnO, potentially altering
their toxicity mechanism and making them unsuitable for specific types of studies. While
these avenues may shed some light into understanding the interplay of nZnO with various
cell types, conclusions drawn from these approaches do not necessarily reflect how
unmodified nZnO interacts with cells.
In addition to biological applications, nZnO are well suited for optoelectronic
devices. Modulating the absorbance, emission spectra and charge carriers in nZnO has
been a goal for optoelectronic device applications. To these ends, one approach has been
to dope various elements in the crystal lattice of ZnO,16-17 while other researchers have
sought to improve ZnO performance by producing highly oriented and defect-free ZnO
nanomaterials. Producing ZnO materials free of defects is hard to achieve, especially at
the nanoscale; some have focused their investigations on ways to reduce the defects
produced when synthesizing nZnO, while others have actively pursued ways to utilize the
various defects states that are inherent to ZnO.
Control of ZnO NM defect states is achieved through various means such as
growth on substrates, annealing in various atmospheric conditions and via numerous
deposition techniques.18-21 For nZnO specifically, achieving control of various defects in
wet chemical methods can be challenging. Many reports have focused on the green
luminescent broad band produced through differing methods, but the precise defect states
or surface species responsible are still controversial, making precise control difficult due
to lack of a known mechanism.22-24
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In this report, we pursued controlling defects of highly pure nZnO that affect the
emission spectra near the band gap, theoretically creating shallow donors such as zinc
interstitials. By controlling these defects, the emission spectra were red-shifted and
broadened, creating strong emissions up to ~430 nm. Additionally, the optical band gap
was red-shifted down to ~3.1 eV allowing excitation sources, such as a 405 nm laser used
in confocal microscopy, to produce sufficient emissions to image the particles without
any other modifications. Through variations in the wet chemical synthesis procedure, we
demonstrate that the described defect states can be systematically controlled for
applications in bio-imaging and potentially optoelectronic devices.
Results and Discussion
ZnO Nanoparticle Synthesis and Characterization
PVP is known to modify the structure and morphology of many different NMs,
including metal oxide NPs.25 The inclusion of PVP in synthesis procedures has been
shown to act as a surfactant, stabilizing agent, dispersant, binding agent and a capping
agent to obtain better dispersions of hydrophobic materials.25 In this report, it was
determined that the PVP content, annealing temperature and the ratio of water to zinc
acetate (ZnAc) were the three key factors that affect the defect states of nZnO. The asprepared nZnO, to which various amounts of PVP were added pre-synthesis, produced
nZnO with an average crystal sizes near 10 nm in all cases (Figure S4.1a-c). Similar
methods, though lacking PVP, have demonstrated the ability to control the average
crystal size of the nZnO by varying the amount of water added during synthesis to
produce nZnO with a broad range of sizes - from ~4 nm to ~50 nm. The addition of PVP
into the solution with the zinc precursor (2:1 PVP:ZnAc; w/w) removed the ability to
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control the size of the particles, regardless of the ratio of water to zinc acetate. For this
reason, any changes in the physical properties of these newly synthesized nZnO are not
size related effects. It is possible that PVP is coordinating the NPs in the cavities of the
polymer during crystal growth and/or capping the particles and restricting their growth,
as theorized in reports for other types of NPs.25
In our procedure described here, the nZnO produced have a similar morphology
to that in other reports; nearly spherical ZnO crystals that form spherical aggregates
(Figure S4.1). One consequence of including PVP in the synthesis is that the as-prepared
NPs retained some of the polymer and other species from the precursors and solvents.
Annealing was performed to remove residual polymer and precursor species to obtain a
highly pure nZnO sample. The Thermogravimetric Analysis (TGA) plot of nZnO
synthesized with PVP (Figure 4.1a) demonstrates that after only 10 minutes of annealing
at 450˚ C, no additional mass loss is evident, even when increasing the temperature to
575˚ C. To confirm the complete loss of retained chemical species, FTIR was utilized to
evaluate the removal of the retained chemical species in the sample when annealed at
various temperatures for 10 minutes. As seen in Figure 4.1b, after reaching 450˚ C, all the
bands associated with the precursors and PVP have effectively been removed and even
the band associated with O-H stretching group at ~3400 cm-1 is almost entirely
eliminated. XPS confirmed the results of the post annealed samples, with only zinc,
oxygen, and carbon atoms (associated with carbon dioxide) detected in the spectra (SI
Figure S4.2).
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Figure 4.1
(a) Thermogravimetric Analysis plot of nZnO synthesized with
Polyvinylpyrrolidine (PVP) demonstrating the mass loss is complete after 10 minutes
of annealing at 450˚ C. (b) FTIR spectra of PVP, the as-prepared nZnO and annealednZnO at various temperatures for 10 minutes. FTIR data confirms that after 10
minutes of annealing at 450˚ C that no other chemical species from the precursors are
retained with the NPs.
As annealing can induce crystal growth, XRD analysis was performed and it was
determined that the average crystal was ~15 nm; an increase of only ~5 nm (SI Figure
S4.1d-f). The modest increase in nZnO size was confirmed with TEM. It was noteworthy
that upon thermal treatment the color of the samples visibly changed from an off-white to
light yellow. It was this observation that prompted further investigation into the physical
and optical properties of these nZnO.
Raman spectroscopy was employed to investigate the potential changes in
vibrational properties, verify the sample purity and assess defects induced during the
synthesis and annealing procedure. Figure 4.2, shows the low temperature (10 K)
resonant UV Raman spectra (325 nm excitation) for bulk ZnO and three samples of the
nZnO produced with varying PVP to zinc acetate ratios. The E1 longitudinal (LO) phonon
modes are enhanced under resonant conditions. In the bulk ZnO sample, the first-order
LO phonon peak appears at 584 cm-1 and the second-order (two-phono) peak appears at
1164 cm-1.26-28 Interestingly, a systematic downward shift of the LO phonon peaks was
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observed with increasing PVP content. The initial downward shift of the peak, when
compared to the bulk nZnO sample (580 vs 584 cm-1), is likely due to phonon
confinement associated with the smaller particle sizes.29-31 However, as discussed above,
all the nZnO samples produced were ~15 nm in crystal size, so the continued shift of the
peak, down to 574 cm-1 for the sample with the highest PVP content, is not likely due to
phonon confinement from decreasing crystal size. The systematic shift of the phonon
peak correlates with the increasing intensity of the peak that appeared in the spectra at
470 cm-1. The E2 (High) phonon mode that should appear at 437 cm-1 was ruled out as
being responsible for the peak found at 470 cm-1, due to the large frequency difference,
the fact that it was not observed in the bulk ZnO and is not commonly seen in resonant
Raman spectra of ZnO.28,32 As we noted, the intensity of this peak increased with
increasing PVP content. We attribute this peak to defect(s) present in the nZnO because
all the residual impurities retained from the synthesis procedure were removed during the
annealing process. Increasing amounts of defects would also explain the continued shift
of the LO phonon modes to lower wavenumbers. As the defect concentration increases,
the phonon mean free path would decrease due to scattering by defects, therefore
shortening the effective phonon confinement length and inducing the observed systematic
shift of the peak,33 similar to size related phonon confinement. To further investigate the
defect(s) responsible for the origin of the peak found at 470 cm-1, photoluminescence
(PL) was employed.
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Figure 4.2
(a) Low temperature (10 K) resonant Raman spectra (325 nm laser) of
bulk ZnO and the nZnO synthesized with various amount of PVP. Spectra shows a
systematic shift of the LO phonon peaks as the defect related peak centered at 470
cm-1 increases in area. (b) Zoomed in spectra of the defect related peak and the 1 LO
phonon mode to highlight the systematic shift of the peak as the defect related peak
increases in area. This systematic shift is likely due to phonon confinement due to
increases in defects present in the ZnO NPs.
Photoluminescence (PL) is often utilized to assess nZnO-associated defects as
they produce various energy states and optical transitions that are within the band gap
region. Numerous papers have reported on how the different emission peaks relate with
various defects,32, 34-39 but many of the conclusions remain controversial. In our attempt
to determine the origin of the defects, low temperature (10 K) PL was collected and
associated with the energy transition modes commonly reported in the literature. Given
the systematic shift of the LO phonon modes and the new peak that was observed in the
Raman spectra, PL was first collected for samples that have various ratios of PVP to zinc
acetate (PVP:ZnAc; w/w), while water content and annealing temperature were held
constant. As seen in Figure 4.3a, varying the ratio of PVP systematically altered the PL
emission spectra as it did in Raman spectroscopy. Modest changes were noted in the
lower PVP:ZnAc ratios, but a significant broadening of the emission peak evolved as the
ratio increased. At the highest PVP ratios, the difference in PL emissions was negligible.
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As such, subsequent synthesis studies varying the annealing temperature and water
content utilized the 2:1 PVP:ZnAc for the synthesis.

Figure 4.3
Low temperature Photoluminescence (PL) spectra of the nZnO
synthesized by varying different parameters in the synthesis procedure. (a) PL
spectra of the nZnO synthesized with various amounts of PVP while all other
parameters are kept constant. At low PVP:Zinc Acetate (ZnAc) ratios, little change
in the PL spectra is noted. As the amount increases, the well- defined peaks broaden
and extend into the visible spectrum. (b) PL spectra of the nZnO annealed at various
temperatures. The unannealed sample spectra extends further into the UV range,
likely due to the presence of various retained species from the synthesis procedure.
As the annealing temperature increase, the main peak in the spectra red-shifts and
broadens out to ~450 nm. At the highest temperature used, the broad green emission,
commonly reported on nZnO, becomes apparent. (c) PL spectra of the nZnO with
various amounts of water added in the synthesis. At relatively high additions of water,
the main broad peak narrows likely due to changes from a zinc rich environment to
a more balanced oxygen to zinc environment. (d) PL spectra of ZnO NPs synthesized
using various methods (ethanol as the solvent, Flame spray pyrolysis (FSP),
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diethylene glycol as the solvent (DEG) and micron sized (Bulk) ZnO) to demonstrate
the extreme difference of the new nZnO compared to other commonly used methods.
Utilizing the nZnO sample produced with a PVP to zinc acetate ratio of 2:1,
additional PL spectra were obtained to evaluate how the changes in surface chemistry,
from annealing at various temperatures, impacted the emissions of the sample. As seen in
Figure 4.3b, the as-prepared sample’s PL spectrum has a peak centered at ~365 nm,
which is potentially influenced by the retained species from the precursors on the surface
of the particles. However, even after annealing at 350˚ C, the temperature at which the
majority of the impurities were removed (Figure 4.1), the PL emission has an apparent
red-shift and the peaks are better defined. Once annealing temperature reaches 400˚ C,
the PL emission peak starts to broaden and extends into the visible region. Since the
samples annealed at or above 450˚ C are highly pure nZnO, the origin of the visible
emission is likely due to defects in the crystal structure and not from interactions between
ZnO and retained chemical species from the precursors. At annealing temperatures above
500˚ C, only modest changes are observed in the violet/blue range of the PL spectra and
the broad defect-related green emission peak around 575 nm, often attributed to oxygen
vacancies,40 becomes evident. Since the focus of this report is primarily to obtain a highly
pure nZnO, relatively free of defects related to the broad green emission, all subsequent
samples were made with a 2:1 PVP:ZnAc ratio and annealed at 500˚ C.
The final component varied in the synthesis procedure was the volume of water
added to the solution (Figure 4.3c). According to published reports on a similar method,
the precise control of the nZnO crystal size is dependent upon the ratio of water to zinc
acetate,41 as water is a source for the oxidation of the zinc ions during the Ostwald
ripening process. As discussed previously, there were no changes to the crystal size found
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by varying the amount of water added during this synthesis procedure and therefore we
ruled out effects due to alterations in the crystal size. Surprisingly, it was observed that
the ratio of water to zinc acetate had a more significant impact on the formation of defect
states than the ratio of PVP to ZnAc or the annealing temperature (Figure 4.3c). Low
ratios of water in the synthesis procedure create a zinc-rich environment, potentially
allowing for the production of intrinsic defects such as interstitials and antisites, as well
as large portions of the crystal surface terminating in zinc atoms. A systematic change in
the PL emission was demonstrated but it was noted that increasing amounts of water
drastically reduced the strong emission near and above 400 nm. The single emission peak
at 368 nm, which correlates with the commonly reported near-band-edge emission, is the
only significant peak noted at higher water to ZnAc ratios. Its presence could be due to
the reduction of zinc to oxygen ratios, creating a more balanced zinc to oxygen
environment, therefore, allowing for better oxidation and formation of the crystals. From
these results, we utilized the particles made with a 1:5 water to zinc acetate (w/w) ratio
for fluorescence imaging studies.
The systematic control of PL emission spectra associated with nZnO was
achieved by varying the PVP content, annealing temperature and water ratios. To
demonstrate the significant changes in the defect content utilizing this new method, the
PL emission spectra of other ZnO NPs, synthesized using a variety of methods, were also
plotted and compared with our nZnO sample found to contain the strongest emissions in
the violet/blue region (Figure 4.3d). A good majority of papers published have focused
on the defects related to the broad green emissions observed near 575 nm in nZnO. This
emission is generally attributed to oxygen vacancies and several of these reports focus on
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the origin of this feature and ways to induce its formation. However, as the inclusion of
PVP largely restricts the formation of the defects responsible for this broad peak in this
synthesis procedure, we chose to further investigate the emission in the 365-450 nm
range induced by this method.
In order to get reasonably well assigned peak positions, PL emission spectra with
well-defined peaks were first deconvoluted. These peak positions were then assigned to
the spectra generated from the nZnO that contained a relatively large number of defects
and broad peaks in the violet to blue region. As seen in Figure 4.4a, only four significant
peaks were found that contribute to the emissions of the sample produced with a low
number of defects. The main peak at 3.36 eV (369 nm) is related to the band gap of the
material and the peak found at 3.32 eV (374 nm) is attributed to free excitons.36 The peak
found at 3.24 eV (383 nm) has been reported as a phonon replica of the exciton peak and
the last peak found at 3.07 eV is often attributed to zinc vacancies. In contrast, the sample
with a relatively high number of defects (Figure 4.4b) was determined to contain seven
different peaks. The main contributors to the broadening of the emissions were found at
positions that have been reported to be related to transitions involving zinc interstitials
and zinc vacancies. The three new major peaks near 3.14 eV, 3.07 eV and 2.97 eV are
often attributed to transitions from zinc interstitials to the valence band, the conduction
band to zinc vacancies and the conduction band to oxygen interstitials respectively.36 It is
also possible that some of these emissions may arise from interface traps as reported for
ZnO thin films,42 as the crystals are bound together in larger aggregates. However, there
has been no clear consensus on which defects are responsible for the observed emission
in this region. Various experimental procedures have assigned specific peak positions to
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the various native defect states, whereas reports relying on theoretical calculations have
demonstrated that some of these defects are unlikely to occur due to diffusion rates and
the required formation energies.22-24 Regardless of the origin of the defects, many are
regarded as donors in the n-type conductivity of ZnO. Since a relatively high number of
these defects are present, we wanted to evaluate how these defects affect the band gap of
our new samples.

Figure 4.4
Deconvolution of the low temperature photoluminescence spectra of
nZnO synthesized with (a) no PVP and (b) a 2:1 (w/w) PVP to zinc acetate ratio. (a)
The NPs with low defect states and well-defined peaks were first deconvoluted to
assign positions and acquire reasonable peak widths for the near band edge related
emissions. (b) The nZnO sample with a relatively high number of defects shows
multiple peaks related to various defects formed during the new synthesis procedure.
UV-Vis diffuse reflectance spectra were recorded to determine the influence these
defects have on the optical band gap of the material. For reference, nZnO produced using
the most similar reported method was plotted against some of the new samples. As can be
seen in Figure 4.5, the samples produced using different ratios of PVP and annealed at
500˚ C induce a significant shift of the band gap. The non-annealed sample that utilizes
the most similar synthesis procedure produced nZnO with a band gap estimated at ~3.31
eV, which is close to the commonly excepted value of 3.37 eV. However, the samples
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produced with the new method that have relatively high concentrations of defects, created
a dramatic shift of the band gap to as low as 3.08 eV. This change of nearly 0.3 eV from
the commonly accepted value of the band gap is usually obtained through doping of other
elements into the crystal lattice.

Figure 4.5
UV-Vis spectra of the new nZnO synthesized with various amounts of
PVP compared to the most similar reported method using DEG as a solvent. The UVVis spectra was converted into a Tauc Plot (inset) to determine the optical band gap
of each sample. The DEG method produced nZnO with an optical band gap of ~3.31
eV whereas the new method shifted the optical band gap to below 3.1 eV.
To verify the lack of metal impurities, ICP-MS measurements were performed.
When compared to the ~2700 ppb of zinc ions from the nZnO, less than 1 ppb of metal
contamination was detected (Table S4.1). Taken together, these evaluations on the new
nZnO led us to conclude that the alterations in the properties of the NPs are due to defects
induced by this synthesis method and are not related to changes in the crystal size,
retained chemical species or impurities. Since the optical band gap had such a dramatic
shift due to these defects and a relatively narrow emission was created in the visible
region, studies were performed using these new nZnO for bio-imaging applications.

121
Fluorescence Imaging
Fluorescence microscopy was employed to assess whether the new nZnO could
be imaged based on their changes in optical properties and the observed shift of the
optical bandgap to ~3.1 eV (400 nm). Confocal microscopy is commonly used in
biological imaging and the instrument is generally configured with a 405 nm laser to
image fluorescent dyes such as DAPI or Hoechst that stain the nuclei of cells. Since the
band gap of the new nZnO is near 400 nm, a 405 nm laser was used as an excitation
source. Figure 4.6a shows the emission spectra recorded using the confocal microscope.
When compared to the broad green emission spectra of nZnO, a relatively narrow
emission peak was recorded for this new nZnO and is easily distinguishable from other
commonly used fluorescent stains. To demonstrate that the fluorescence stems from the
NPs, fluorescence and bright field images were collected by individual detectors and
overlaid (Figure 4.6b-d). Additional images that were acquired with higher magnification
and resolution show the large agglomerates are comprised of the smaller individual
aggregates that are seen in the TEM images (SI Figure S4.3).

Figure 4.6
(a) The emission spectra of the nZnO recorded with a confocal
microscope using a 405 nm laser as an excitation source. Using a 100x objective, the
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fluorescence image (b) of the nZnO and bright field (c) images were collected and
overlaid (d) to demonstrate that the fluorescence is from the new nZnO.
Another obstacle to the development of new imaging modalities is
photobleaching. Photobleaching is the irreversible alteration of a dye or fluorophore
leaving it unable to fluoresce and is a common issue in immunofluorescent imaging. The
emergence of fluorescent quantum dots, such as CdSe, demonstrate that NMs hold certain
advantages over other more traditionally used fluorescent stains, such as their narrow
emission spectra, longer fluorescence decay time and their ability to resist
photobleaching.5 In order to assess the ability of our new nZnO to resist photobleaching,
their fluorescent signal was monitored over time during continuous exposer to laser light.
Specifically, nZnO were excited with a 405 nm laser for twenty minutes and single plane
images were acquired every minute. Time series were collected utilizing different
objectives, and regardless of the magnification, no changes in fluorescence were detected
(Figure 4.7). Since the images might appear to be replicates, each time series was
exported into a video format to further demonstrate the stability of the NPs over time
(See SI Video).

Figure 4.7
Times series fluorescent images of the nZnO over a 20 minute period
with a (a-e) 20x objective and a (f-j) 40x objective. The NPs were subjected to 20
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minutes of laser exposure and no apparent decrease in fluorescence intensity was
noted, demonstrating their resistance to photobleaching. Like quantum dots, the
fluorescence stems from the physical properties of the NPs and is proposed to stem
from transitions between energy levels due to the defects present in the samples.
Many of the problems associated with using nZnO in bio-imaging are due to the
broad green emission peak associated with surface defects. When introduced into
biological media, various components such as carbonates and phosphates react with the
surface of nZnO10-12, 43, 44 and can potentially reduce or completely remove the
fluorescence associated with surface defects. In our new nZnO, the defects in this system
can persist throughout the crystal lattice, such as zinc interstitials, and perhaps stabilize
their ability to fluoresce even in cellular media. Having a pure, unmodified and naturally
fluorescent nZnO sample that is excitable with a laser source commonly available in
fluorescent microscope systems can expand the use of nZnO in fluorescence imaging. In
addition, a stably fluorescent nZnO will also facilitate research focused on understanding
nZnO interactions with living systems.
In order to demonstrate the ability to image nZnO in cellular media conditions,
live-cell imaging was performed using T47D breast cancer cells. The cells were treated
with 30 μg/mL of nZnO and incubated for either 2 or 24 hours. Cells were then stained
with CellMask Orange Plasma Membrane for 30 minutes prior to imaging. For a control,
untreated T47D cells were stained with CellMask Orange only and imaged using the
same configuration and laser settings to rule out any auto-fluorescence generated by the
cells in the nZnO channel. As seen in Figure 4.8, the untreated cells have little to no
apparent fluorescence in the nZnO channel. After 2 hours of incubation, a few nZnO are
seen in the same plane as the cells and appear to randomly settle down and associate with
the membrane of the cells. No apparent changes in cellular morphology were noted at this
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time point. Surprisingly, after 24 hours of nZnO exposure, no particles were found
around the exterior of the cells, and in stark contrast to the fluorescence observed at 2
hours, the only fluorescence detected appears to be from nZnO that have been
internalized within the plasma membrane. It is unlikely that every NP was internalized by
the cells, yet no particles could be found in the exterior. It is possible that the noninternalized nZnO underwent dissolution or transformed into zinc carbonate or hydroxide
species and were no longer fluorescent. However, many NPs were still detectable in the
interior of the cells after 24 hours and may resist degradation upon cellular
internalization. Another noteworthy feature from this experiment was that the
morphology of the T47D cells changed dramatically. The cells rounded up and appear to
be detaching from the culture plate. Furthermore, cells showed evidence of blebbing; the
bulging of the cell membrane, characteristic of cytoskeletal breakdown that accompanies
apoptosis.
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Figure 4.8
Confocal images of T47D (breast cancer) cells stained with CellMask
Orange. The top row depicts untreated T47D cells to assess any auto-fluorescence
generated using the same laser settings in the 405 nm laser channel. The second row
depicts the T47D cells after 2 hours of nZnO treatment. Little to no change in cell
morphology is noted. The bottom row depicts T47D cells after 24 hours of nZnO
treatment. The cellular morphology is drastically changed, many blebs are noted, and
essentially all NPs that are detectable appear to have been internalized.
Despite the number of studies that investigate nZnO, many questions remain
regarding toxicity mechanisms and their inherent selectivity towards cancer cell
destruction. Some of the more commonly cited mechanisms of nZnO toxicity has been
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attributed to ROS generation, particle dissolution, and to a lesser extent, membrane
damage.1, 45-48 Since there is still controversy on the primary source of toxicity, the
unmodified fluorescent nZnO described here may help elucidate the various toxicity
mechanism(s) and give insight into why reports demonstrate cell type selective toxicity.
After 24 hours post treatment, a nZnO fluorescence signal was still detectable in the
interior of the cells and may suggest NP internalization is key to asserting the NPs toxic
effects. Even though these interesting observations were made, the source(s) of the
changes in cellular morphology were not deciphered and is the goal of future projects.
Utilization of zinc ion specific dyes may allow for simultaneous tracking of both nZnO
and the release of zinc ions from nZnO dissolution to help elucidate the complex nature
of these interactions. Other specific labels, such as fluorophores specific to various
endocytic processes and ROS sensitive dyes, would be keys to understanding the
interactions of the nZnO with cells, but is beyond the scope of this paper. Other future
work will look into reducing the size of the aggregates, stabilizing the particles in
solution and conjugating antibodies to the surface of the NPs to facilitate their use as a
potential bio-label for targeting specific cellular compartments.
Conclusion
Achieving systematic control of native defects in ZnO NPs can often be
challenging, especially in wet chemical methods. This work demonstrates the ability to
control specific defect states of nZnO through modifications to the synthesis that
modulate key properties of the material. The reduction of the band gap to ~3.1 eV and the
shift of the emission spectra to the visible region allowed for imaging of the NPs using
traditional fluorescence microscopy techniques. The ability to perform live cell imaging
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with essentially pure nZnO may help in deciphering their complex interactions with
various cells types and understanding their cancer cell selective toxicity. The relatively
low toxicity of nZnO compared to other quantum dots such as cadmium chalcogenides
may also make them more suitable as a bio-label in fluorescence imaging. Additionally,
the alterations to the physical properties discussed in this report may also be exploited in
other applications such as optoelectronic devices. Further research is needed to fully
investigate their utilization in these various fields but, based on these studies, there is
promise for them to be used in a variety of applications.
Experimental Section
ZnO Nanoparticle Synthesis
The new synthesis procedure for producing nZnO was adapted from previous
procedures with various modifications.41 Zinc acetate dihydrate was used as the zinc
source and diethylene glycol (DEG) as the solvent. Three parameters were varied to
control the defects in the wet chemical synthesis; the amount of polyvinylpyrrolidine
(PVP), water, and annealing temperature. The solution was created first by the
simultaneous addition of PVP (molecular weight 58k) and zinc acetate, followed by the
addition of DEG and initially heated to 80˚ C. Various amounts of water were then
added, the temperature brought up to 150˚ C, and then held for 75 minutes. Once the
solution cooled to room temperature, the samples were centrifuged at 41,410 X g to
remove the DEG and subsequently washed with absolute ethanol. The pellet was dried
overnight at 60˚ C and then annealed in air at the various temperatures indicated.
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Characterization
The nZnO samples were characterized using several techniques. X-ray diffraction
(XRD) spectra were collected using a Rigaku Miniflex 600 X-ray diffractometer and used
to determine the crystal phase, lattice parameters and to estimate the average crystal size
using Rigaku PDXL software version 1.8.0.3. Thermal gravimetric analysis (TGA) was
performed using a Netzsch STA449F1 TGA-DSC to define the ideal temperature and
time to remove retained chemical species from the synthesis procedure. Transmission
electron microscopy (TEM) was utilized to obtain both average crystal size distributions
and determine the NP morphology using a JEOL JEM-2100 HR analytical transmission
electron microscope. To obtain atomic concentrations and evaluate sample purity, both
X-ray photoelectron spectroscopy (XPS) and Fourier transform infrared spectroscopy
(FTIR) were utilized. A Physical Electronics Versaprobe system with a monochromated
Al Kα X-ray source was used to obtain the XPS spectra and a Bruker Tensor 27
spectrometer was used for FTIR spectra collection. FTIR pellets were prepared by
grinding 1.5 mg of the NP sample with 0.200 g of spectroscopic grade KBr and
subsequently pressed for 4 minutes with 8 tons of pressure. A Malvern Zetasizer NanoZS
was used to collect dynamic light scattering (DLS) measurements by using a
concentration of ZnO NPs of 0.5 mg/mL in nanopure water. For inductively coupled
plasma mass spectrometry (ICP-MS) experiments, the nZnO were dissolved in 25 mL of
highly pure 2% nitric acid solution and analyzed by a Thermo-electron X-series II
quadrupole ICP-MS. The samples were analyzed for various metal contaminations such
as iron, cobalt and nickel against the total zinc content. Raman and photoluminescence
(PL) spectra were measured in backscattering geometry using a Jobin Yvon T64000
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0.64m triple spectrometer equipped with a liquid nitrogen cooled multichannel CCD
detector. Spectra were recorded at 10 K using a variable temperature closed cycle helium
cryostat. Ultraviolet light (325 nm line of He-Cd laser) was used for excitation.
ZnO Nanoparticle and Live Cell Imaging
Confocal microscopy was utilized to image both the nZnO and T47D cells treated
with nZnO. Because this new method of nZnO synthesis achieves a lower band gap of
~3.1 eV, a 405 nm laser was able to be used as an excitation source and nZnO
fluorescence monitored. For live cell imaging experiments, T47D (ATCC HTB-133), a
cell line derived from ductal breast carcinoma (ATCC; Manassas, VA) was maintained in
log phase and cultured in RPMI 1640 media following ATCC recommendations. Prior to
imaging experiments, the cells were washed and resuspended in a custom made RPMI
1640 media free of HEPES, phenol red and phosphate (PPH free RPMI 1640; Thermo
Fisher Scientific; Grand Island, NY) to prevent increased NP dissolution, remove
fluorescent background signal and reduce the chemical transformation of the NPs,
respectively.10, 49 The cells were then transferred to Nunc Lab-Tek II Chambered cell
culture slides (ThermoFisher; Waltham, MA). Following an overnight incubation to
ensure cell adhesion, nZnO were added at a final concentration of 30 μg/mL and further
incubated to allow for nZnO-cell interactions. Control (nZnO-free) cells were cultured in
the same manner to assess auto-fluorescence generated using the 405 nm laser to excite
the nZnO. Prior to imaging, live cells were stained with the plasma membrane stain Cell
Mask Orange (Invitrogen; Carlsbad, CA). In brief, stain was added to culture media for at
a final concentration of 5 µg/ml. All confocal images were acquired with a Zeiss 510
LSM system with the Zeiss Axiovert Observer Z1 inverted microscope and ZEN 2009
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Imaging software (Carl Zeiss, Inc.; Thornwood, NY) utilizing Diode (405 nm) and HeNe
(543) lasers as excitation sources; a Plan-Apochromat 20x/NA 0.8, Fluar 40x/NA 1.3 oil,
or α-Plan Fluar 100x/NA 1.44 oil objective; and band-pass BP filters of 420-480 nm and
550-647 nm to image the nZnO particles and lipid layer, respectively.
Supporting Information
Supporting Information is available from the Wiley Online Library (upon
acceptance) or from the author.
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Supporting Information

Figure S4.1 (a) XRD patterns of as prepared nZnO produced with various amounts
of PVP to zinc acetate (ZnAc). (b-c) TEM images of the as prepared nZnO produced
with the 2:1 PVP to ZnAc ratio. (b) Aggregates are formed from the smaller (c)
individual nZnO crystals. (d) XRD patters of nZnO synthesized with a 2:1 PVP:ZnAc
ratio and various amounts of water added. This demonstrates that the amount of
water added in this synthesis procedure does not affect the size of the crystals. (e-f)
TEM images of the nZnO produced with the 1:250 water:DEG ratio show the size of
the aggregates and verifying the average crystal sizes obtained from XRD. Scale bars
= (b) 200 nm, (c) 5 nm, (e) 200 nm, and (f) 5 nm.
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Figure S4.2 (a-d) XPS scans of nZnO produced with a 2:1 PVP:ZnAc and annealed
at 450⁰ C for 10 minutes. (a) Survey scan of the nanoparticles demonstrates only the
elements Zinc, Oxygen and Carbon were detected. (b-d) Core level scans of the Zn2P,
O1s and C1s regions. The core level scans demonstrate a high purity of nZnO
produced with the only contamination stemming from adventitious carbon due to
atmospheric exposure.
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Table S4.1 Table of ICP-MS measurements of various metals from the nZnO
dissolved in high purity nitric acid. Not even 1 ppb of any other metal was found to
be present in the nZnO demonstrating high purity of the nanoparticles.

Figure S4.3 Images of the nZnO acquired with a Zeiss LSM 880 with Airyscan
using a 405 nm laser for excitation. Images acquired with higher magnification and
resolution demonstrate the larger fluorescent agglomerates are comprised of the
smaller nZnO aggregates (50-500 nm) as seen in the TEM images.
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Abstract
Nanomedicine offers high promise for the treatment of diseases and numerous
novel approaches using nanomaterials have been developed over the years. In this report,
we demonstrate a new strategy utilizing ZnO nanoparticles (nZnO) to trigger the rapid
release of lipid encapsulated contents upon photo irradiation. In vitro studies demonstrate
that encapsulation of nZnO effectively eliminates the toxicity of nZnO but is reestablished upon the triggered release from the lipid coating. Using 5(6)carboxyfluoroscein as a model for hydrophilic drugs, we show the ability to co-load
drugs with nZnO into the liposome. Kinetics studies demonstrate the ability to release the
majority of the dye within 60 minutes post photo irradiation. To further expand upon this,
Jurkat T cell leukemia and T47D breast cancer cells were treated with co-encapsulated
nZnO and the hydrophobic cancer drug Paclitaxel. These studies demonstrate increased
toxicity of the triggered release groups with an extreme difference noted in the T47D
breast cancer cell model. Taken together, these studies demonstrate that this system has
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promise to potentially minimize systemic toxicity while allowing for the localized
selective destruction of cancer.
Introduction
The field of nanobiotechnology is rapidly growing and numerous applications
have been developed utilizing nanomaterials. In particular, researchers have pursued the
use of nanomedicine for the diagnosis and treatment of diseases such as cancer, and many
novel nanostructures offer considerable promise in these areas. Currently, there are
already over 50 FDA approved nanomedicines and numerous others in clinical trials.1
The goal of many of these new technologies is to offer new therapeutic treatment options
or to improve upon already existing technologies through increased efficacy or by
minimizing off-target side effects. In this regard, ZnO nanoparticles (nZnO) have been
utilized in various potential drug delivery devices,2 and have many features that make it a
good candidate for therapeutic applications.
One of the well-known physical properties and proposed toxicity mechanisms of
nZnO is particle dissolution. This feature is enhanced in lower pH environments, such as
in certain tumors or intracellular compartments, and has been exploited as a means to
control drug escape. An example of utilizing the dissolution potential of ZnO is to
encapsulate doxorubicin loaded SiO2 NPs with a layer of ZnO.3 The ZnO layer prevents
premature drug leakage, but when exposed to a lower pH, the quick dissolution of ZnO
induces the release of the drug.
In addition to high dissolution potential, nZnO and numerous other metal oxide
NPs have another property that can be exploited for use as a potential therapeutic. Many
metal oxide NPs show strong photocatalytic activity and reports have demonstrated the
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generation of reactive oxygen species (ROS) from various photocatalytic
semiconductors.4, 5 ZnO nanoparticles, in particular, have been shown to have increased
toxicity towards cancer cells when exposed to UV light.6, 7 Phototherapy treatment
experiments with nZnO have demonstrated increased ROS generation that can lead to
extensive lipid peroxidation of cellular membranes.8-10 Since the peroxidation of lipids
can lead to lipid radicals that propagate throughout the bilayer, this process has been
shown to lead to the rupture of cellular membranes.11, 12 Collectively, the various physical
properties of nZnO have led to the development of novel strategies to combat diseases
and highlight why numerous researchers are pursuing its use as a therapeutic.
In addition to these physical properties, nZnO show inherent selective toxicity
towards various cancer types when compared with the normal non-malignant cell types of
identical lineage.12-14 Reports have shown up to a 33-fold selectivity towards cancerous
cells, which is a higher therapeutic index than reported for many traditionally used
chemotherapeutics using similar assays.15 Importantly, the selective nature of nZnO for
cancers such as squamous cell lung cancer and pancreatic adenocarcinoma has recently
been demonstrated in mouse models and is not just a novelty of in vitro experiments.16, 17
Additional reports have used nZnO structures for both MRI and bio-imaging purposes,
thereby suggesting that nZnO have the potential to be used in both therapeutic and
diagnostic applications as well.17-19
Even though there have been numerous strategies that utilize nZnO for
therapeutic applications, there do exist some limitations to its use. With the high
dissolution potential of nZnO, introduction into biological fluids can induce the
dissolution of the particles before they reach their target site. Additionally, nZnO is prone
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to aggregation, especially in environments with high ionic concentrations such as in
biological fluids. This may also impede their effectiveness as a therapeutic and thus many
reports have looked at ways to achieve stable nZnO suspensions. A common strategy to
stabilize nZnO in solution is to coat the particles with polymers or biomolecules. Lipids
vesicles are already extensively used for drug delivery and may help increase the stability
of nZnO while simultaneously preventing premature dissolution.
Hybrid liposome-inorganic NPs offer an interesting avenue for drug delivery and
due to many of the key attributes of lipids, liposomal formulations make up a large
fraction of the currently FDA approved nanomedicines. Some of the attributes that make
lipids attractive for drug delivery include high biocompatibility, ease of synthesis, various
means of controlling drug release, and targeting by both active and passive processes.1, 20,
21

Since lipids are amphipathic, both hydrophobic and hydrophilic drugs can be loaded

within liposomes. This feature has allowed for their use in both approved nanomedicines
and ongoing clinical trials for both hydrophobic and hydrophilic drugs.1, 20, 21 Many
formulations of liposomes have demonstrated high encapsulation efficiency of both
hydrophobic and hydrophilic drugs which can improve their stability and
pharmacokinetics. However, unmodified liposomes themselves are recognized by the
immune system and are quickly cleared from circulation.22 This drawback has been
overcome by the creation of “stealth” liposomes. For example, the conjugation of
polyethylene glycol (PEG) to the head group of lipids prevents the reticuloendothelial
system from rapidly clearing the stealth liposomes and leads to improved circulation
time.1, 22, 23
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In addition to the conjugation of PEG to lipids, conjugating ligands or antibodies
to liposomes specific for individual cell surface receptors allows for active targeting and
can improve their localization in tissues that over express these surface features.
Additionally, passive targeting has been another avenue that researchers have pursued.
Nanoparticles (NPs) in the size range of 4-200 nm have been shown to accumulate in
tumor environments that have a “leaky” vasculature and avoid clearance due to reduced
lymphatic drainage. This feature is termed the enhanced permeability and retention (EPR)
effect and is present in certain tumor morphologies.24, 25 Targeting capabilities offer the
promise of improved efficacy by high concentrations of the drug being released in the
target area. This can simultaneously reduce the amount of overall drug concentration
needed in hopes of reducing or eliminating unwanted side effects.
The controlled release of liposomal contents has been demonstrated through
various mechanisms. For example, pH sensitive lipids such as
dioleoylphosphatidylethanolamine (DOPE) allow for increased membrane permeability
when incorporated into the bilayer and subsequently exposed to a lower pH
environment.26, 27 As many tumor microenvironments have a relatively acidic pH, this
approach has been pursued as a means to release high payloads of drugs in a localized
area.
With all of the different nanotechnologies that are currently under development,
the promise of improved drug delivery and diagnostic options may allow for increased
patient survival while minimizing side effects commonly associated with current
chemotherapeutics. Since nZnO have numerous promising attributes and lipid carriers are
proven efficient drug carriers, we sought to combine the benefits of both systems. Here
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we report on the first foray, to our knowledge, in utilizing the ROS generating
capabilities of nZnO to trigger the rapid release of cargo contained within a lipid carrier
as a potential new drug delivery strategy.
Materials and Methods
ZnO Nanoparticle Synthesis and Characterization
All ZnO NPs in this study were produced by a forced hydrolysis method that has
been previously reported (see Chapter 4). Zinc acetate dihydrate and polyvinylpyrrolidine
(PVP) were added to diethylene glycol and brought to 80˚ C. Then nanopure water was
added, the solution heated to 150˚ C, and held for 75 minutes. After cooling to room
temperature, the mixture was centrifuged at 41,140 x g and repeatedly washed with
absolute ethanol. The pellet was dried overnight at 60˚ C and pulverized with a mortar
and pestle. The powder was subsequently annealed at 500˚ C for 10 minutes.
NPs were characterized by a variety of techniques including: X-ray diffraction
(XRD), Transmission Electron Microscopy (TEM), Fourier Transform Infrared
Spectroscopy (FTIR), X-ray Photoelectron Spectroscopy (XPS), Inductively Coupled
Plasma Mass Spectrometry (ICP-MS), and Energy Dispersive X-ray Spectroscopy
(EDX). A Rigaku Miniflex 600 X-ray diffractometer was used for XRD measurements to
verify the crystal phase and estimate the crystal size of the NPs. A JEOL JEM-2100 HR
analytical transmission electron microscope was used to acquire TEM images of the
nZnO to verify the crystal size and obtain the NP morphology. To evaluate the sample
purity, a Physical Electronics Versaprobe XPS system and a Bruker Tensor 27
spectrometer FTIR system were utilized. For FTIR experiments, the pellet method was
used where 1.5 mg of the nZnO sample was ground with 0.200 g of spectroscopic grade
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KBr and subsequently pressed with 8 tons of pressure for 4 minutes. For dynamic light
scattering and zeta potential measurements, a Malvern Zetasizer NanoZS was utilized by
suspending 0.25 mg/mL of the nZnO in nanopure water and in 130 mM NaCl. For
gadolinium doped nZnO, the same synthesis procedure was used except that PVP was
excluded and gadolinium acetate was added at the appropriate molar ratio with the zinc
acetate dihydrate. To further evaluate the nZnO purity and to evaluate the doping
concentration of gadolinium in the appropriate samples, ICP-MS was utilized.
Additionally, XRD and electron diffraction patterns were collected using the same
instruments to verify crystal phase purity of the gadolinium doped samples and EDX
measurements were obtained to further verify the gadolinium content.
Encapsulation of nZnO and Cargo
ZnO NPs were encapsulated in soy phosphatidylcholine (Avanti Polar Lipids
Inc., Alabaster, AL) and cholesterol with a 3 to 1 (w/w) ratio. The lipids and cholesterol
(chol) were dissolved in chloroform with a final concentration of 13.33 mg/mL (lipid +
chol). The lipid/chol solution was then put under vacuum overnight to remove all solvent.
To encapsulate the NPs, nZnO was suspended in 130 mM NaCl and sonicated for 45
minutes. Simultaneously, 130 mM NaCl was added to the lipid cake for hydration and
heated in a water bath to 60o C. Upon reaching 60o C, the lipids were briefly sonicated
and then the nZnO solution was added for a final nZnO concentration of 4.07 mg/mL (50
mM) with various nZnO to lipid ratios. The NP/lipid/chol solution was then sonicated in
a bath sonicator for 1 hour at 60o C and stored at 4o C until use. To encapsulate the
fluorescent dye 5(6)-carboxyfluoroscein (CF) with the nZnO, the same procedure was
carried out except the solution was comprised of 30 mM CF and 100 mM NaCl to
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prevent osmotic pressure artifacts when resuspending the lipid coated particles in 130
mM NaCl. The CF/NaCl solution was pH adjusted to 7.4 and 9.85 by adding the
appropriate amounts of NaOH. For paclitaxel (PTX) loading, a 2 mM stock solution was
first prepared by dissolving PTX (Alfa Aesar, Haverhill, MA) in DMSO. To coencapsulate PTX with the nZnO, an appropriate amount of the PTX stock solution was
added to the lipid/chol mixture while in the chloroform solution and then all subsequent
procedures were carried out as described above.
Simulated Drug Release
The fluorescent dye, CF, was utilized as a model for hydrophilic drug release and
was co-loaded with nZnO as described above. The dye was loaded at 30 mM, well above
the self-quenching concentration through the passive loading process. To remove the CF
from the exterior solution, the encapsulated nZnO/CF was centrifuged at 296 xg for 2
minutes and the solution was exchanged with 130 mM NaCl repeatedly until the solution
was clear. Fluorescent measurements were performed using a FluoroMax-4
spectrofluorometer with a working range of 285-750 nm. An excitation of 480 nm was
used and emission spectra were collected from 490-600 nm. A self-quenching curve of
CF was generated by collecting fluorescent measurements with a various concentration of
free CF in 130 mM NaCl to verify that the working concentrations were within the linear
fluorescent region (Figure S5.1). Baseline measurements were first collected (Fbaseline)
and then a 30 W, 365 nm LED lamp was used as a UV source to cause photoexcitation of
nZnO and induce the triggered release of the fluorescent dye (F). To induce full release of
the encapsulated dye (Ftotal), 20 uL of 5% Triton-X stock was then added to the solution.
The percentage of released CF was determined by:

149
% 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 = (𝐹 − 𝐹𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 )/ (𝐹𝑡𝑜𝑡𝑎𝑙 − 𝐹𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 ) 𝑥 100
Cell Culture
To assess the effect that the triggered release of encapsulated nZnO (Enc-nZnO)
and encapsulated nZnO with PTX (Enc-nZnO/PTX) had on the cytotoxicity of cancer
cells, two human cell lines were utilized; Jurkat (ATCC TIB-152), a suspension cell line
derived from acute T cell leukemia and T47D (ATCC HTB-133), an adherent cell line
derived from ductal breast carcinoma (ATCC; Manassas, VA). Both cell lines were
cultured in log phase using RPMI 1640 media supplemented with 10% FBS (fetal bovine
serum), 1% penicillin/streptomycin, 2 mM L-glutamine, and for T47D cells, 0.2
Units/mL of bovine insulin per ATCC (American Type Culture Collection)
recommendations.
ZnO NP and Live Cell Imaging
To evaluate the encapsulation of nZnO within a lipid membrane, imaging
experiments were performed. The Enc-nZnO sample was transferred into a Nunc LabTek II Chambered Coverglass 2 that contained 130 mM NaCl. The lipids were then
stained utilizing the plasma membrane stain Cell Mask Orange (Invitrogen; Carlsbad,
CA) at a final concentration of 5 μg/mL, 30 minutes prior to imaging. For live cell
imaging of T47D breast cancer cells, the cells were transferred to a Nunc Lab Tek II
chamber in RPMI 1640 two days prior to imaging at a concentration of 100,000
cells/well and allowed to attach to the cover slip. After 24 hours, the media was gently
aspirated and then replaced with HEPES-free, phenol-free, and phosphate-free RPMI
1640 (PPH free RPMI 1640) (custom order Thermo Fisher Scientific; Grand Island, NY).
The media exchange was carried out to prevent the transformation and dissolution of
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nZnO induced by phosphate and HEPES, respectively.28-30 Phenol red was excluded to
prevent fluorescence emissions during the imaging experiments. The cells were treated
with Enc-nZnO 24 hour before imaging at a final concentration of 81.4 μg/mL (1 mM)
for the non-triggered released experiments. In the triggered release group, the T47D cells
were treated with a final nZnO concentration of 20.3 μg/mL (250 μM). Cell Mask Orange
was added to the media and cultures incubated an additional 30 minutes prior to imaging.
Confocal microscopy was used to image both the Enc-nZnO and T47D cells
treated with Enc-nZnO. Images were acquired using a Zeiss 510 LSM system with the
Zeiss Axiovert Observer Z1 inverted microscope and ZEN 2009 Imaging software (Carl
Zeiss, Inc., Thornwood, NY) utilizing different objectives and band-pass filters. We
recently reported on a new synthesis procedure to produce essentially pure nZnO that
lowers the band gap to ~3.1 eV allowing for the 405 nm laser to be used as an excitation
source to produce a narrow fluorescence emission band from nZnO (410-430 nm; see
Chapter 4). Using a configuration specific for the excitation and emission of the
synthesized nZnO and the plasma membrane stain, images were collected with either a
Plan-Apochromat 20x/NA 0.8 or Plan-Apochromat oil 63x/NA 1.4 objective. The diode
(405 nm) and HeNe (543 nm) lasers were used as excitation sources, and band-pass
filters of 420-480 nm and 550-647 nm were used to image the nZnO and lipid layer,
respectively.
Viability Studies
For viability assessments, both Jurkat and T47D cells were cultured following
ATCC recommendations noted above. For the Jurkat T cell line, the cells were first
washed with PPH free RPMI 1640 and then seeded at a concentration of 2.5 x 105
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cells/mL using the same media in a 96 well plate. For T47D cells, the cells were first
seeded in the culture media at 1.0 x 105 cells/well in a 24 well plate the day prior to
treatment to allow for cell attachment. The media was then gently aspirated and replaced
with the PPH free RPMI 1640 media prior to NP treatment.
The Enc-nZnO and Enc-nZnO/PTX stocks were prepared, as indicated above, at a
nZnO concentration of 4.07 mg/mL (50 mM) and pH=7.2 to avoid potential effects to
cellular viability using a higher pH. For the free nZnO (non-encapsulated) controls, a
fresh stock was prepared for each viability experiment by first suspending the nZnO in
nanopure water at a concentration of 4.07 mg/mL (50 mM) and sonicated for 20 minutes.
The 2 mM PTX-DMSO solution was used to assess free PTX effects on the cells as a
control. Prior to treatment, PTX-DMSO solution was added to fresh cellular media at the
desired PTX concentration making the final DMSO concentration ≤ 0.2 %. In the case of
free nZnO, Enc-nZnO and Enc-nZnO/PTX, the appropriate amount of the stock solution
was added to fresh cellular media to achieve a final nZnO concentration of 1.63 mg/mL
(20 mM) prior to addition.
Once treated with NPs, the cells were then cultured for 48 hours at 37 oC and 5%
CO2. For samples receiving UV irradiation, cultures were subjected to photo-irradiation
1.5 hours post NP treatment using the same 30 W, 365 nm LED lamp as in the simulated
drug release studies. After optimizing the UV irradiation protocol, we determined the
required UV exposure to be 3 minutes for Jurkat cells and 2 minutes for T47D cells to reestablish the toxicity of the nZnO while minimizing effects to the cells viability. Cell
viability was assessed using the Alamar Blue metabolic assay. Alamar blue was added to
the wells at a final concentration of 10% 44 hours post treatment and incubated for an
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additional 4 hours. The fluorescence intensity measurements were performed using a
Biotek Synergy MX plate reader using an excitation/emission of 530/590 nm.
Results
ZnO NP Synthesis and Characterization
ZnO nanoparticles (nZnO) were synthesized using a previously reported wet
chemical method utilizing DEG as a solvent (see Chapter 4). This particular synthesis
method was chosen as it produces nZnO with a narrow visible fluorescence band that
allows for fluorescent imaging using traditional fluorescent microscopy techniques. XRD
measurements verified the hexagonal wurzite crystal structure, with no other phases
detected and an average crystal size of 15.1 ± X nm. TEM images (Figure 5.1),
demonstrate that the nZnO form larger aggregates of 50-400 nm comprised of smaller
nZnO crystals of ~15 nm, thereby confirming the XRD analysis. Dynamic light scattering
measurements in nanopure water and 130 mM NaCl give the average hydrodynamic size
(HDS) of the aggregated nZnO as 317 ± 2.87/2092±149.4 (Z-avg.; d.nm) with a
polydispersity index (PDI) of 0.122/0.4, respectively (Figure S5.2 for size distributions).
FTIR, XPS and ICP-MS measurements were used to confirm sample purity. With the
exception of small amounts of carbon dioxide impurities and hydroxide formation, the
nZnO are essentially pure (Figure S5.3). A more extensive characterization of this nZnO
formulation has already been reported (see Chapter 4).
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Figure 5.8
(A) XRD pattern of the nZnO synthesized with calculated average
crystal size of 15 nm. (B) TEM image of the aggregates composed of the smaller ZnO
NP crystals (scale bar- 50 nm). (C) Electron diffraction pattern of the nZnO (scale
bar 5/2 nm).
Encapsulation, Imaging and Viability Assessments of Enc-nZnO.
Sonication of lipids above their transition temperature has been used to produce
single bilayer lipid vesicles and is a common method employed for producing small
liposomes.31, 32 In order to encapsulate nZnO, we followed this same strategy but
included the nZnO during the sonication procedure. To demonstrate good encapsulation
of the nZnO, confocal microscopy was employed. As seen in Figure 5.2, the fluorescent
signal from the lipid membrane stain overlays with the fluorescent nZnO, demonstrating
good encapsulation of the nZnO. Dynamic light scattering measurements were
subsequently performed on the encapsulated ZnO NPs (Enc-nZnO). Interestingly, a
drastic decrease of the hydrodynamic size (HDS; Z-avg.; d.nm) was observed
(739.5±15.5) when compared to the salt solution control and the size distribution is more
similar to the free nZnO in nanopure water (Figure S5.2). This feature is attributed to the
stabilization of the nZnO in the solution. We believe the hydrophilic surface of the lipid
encapsulation helps prevent agglomeration of the nZnO, which is generally observed in
higher ionic concentrations.33 This stabilization was consistent over many months,
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preventing the particles from agglomerating and allowing for the Enc-nZnO to be stored
and used for subsequent experiments.

Figure 5.2
Confocal microscopy image of the (A) fluorescent nZnO, excited by a
405 nm laser, (B) the lipid membrane stained with CellMask Orange, and (C) an
overlay of A and B, demonstrating efficient encapsulation of the nZnO.
To determine the impact encapsulating nZnO has on toxicity, both Jurkat T cell
leukemia (suspension) and T47D breast cancer (adherent) cells were treated with EncnZnO for 48 hours. NPs sedimentation and, more specifically, the tendency for nZnO to
agglomerate and become an unstable suspension in cellular media, has been shown to
result in both decreased viability of adherent cells and increased viability of suspension
cells.34, 35 As our Enc-nZnO have a decreased HDS and the lipid coating prevents their
agglomeration in salt solutions, their toxicity profile could conceivably be impacted and
may increase the uptake of the NPs as seen in other reports.36 However, the lipid
encapsulation could also reduce interactions of the highly reactive surface of nZnO with
cells or reduce/eliminate its dissolution in cellular media which could significantly affect
nZnO interactions with cells and influence their toxicity.
As can be seen in Figure 5.3, coating nZnO with lipids effectively removes the
toxicity for both Jurkat and T47D cancer cell types (No UV group: compare blue bars
across the 3 panels). Treatments were conducted with concentrations up to 10 times the
IC50 of the bare nZnO samples (~12.2 μg/mL), and no appreciable toxicity was observed
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with treatment as high as 122.21 μg/mL. Further studies demonstrated the ability to
trigger the release of the Enc-nZnO using phototherapy by irradiation with a 365 nm LED
UV lamp. Only a few minutes of UV exposure was required to effectively restore the
toxic effects of the NPs to the cancer cells (Figure 5.3).

Figure 5.3
Viability profiles of (A) Jurkat T cell leukemia treated with free nZnO
(non-encapsulated), (B) Jurkat cells treated with Enc-nZnO and (C) T47D breast
cancer cells treated with Enc-nZnO for 48 hours. (B & C) The non-UV groups (blue
bars) show that the membrane encapsulation of nZnO protects the cells from the toxic
effects of the NPs. The UV treatment groups (green bars) demonstrates that the toxic
effects of nZnO are reestablished by the triggered release of the particles, most likely
due to ROS generated from the nZnO and subsequent shedding of the lipid coating.
UV exposure= 3 minutes for Jurkat T cells; 2 minutes for T47D cells.
To further demonstrate both the protective nature of encapsulating nZnO and the
re-establishment of the toxicity upon triggered release, confocal microscopy was utilized
to image the T47D cells with Enc-nZnO after 24 hours of treatment. As can be seen in
Figure 5.4 (middle row), even at concentrations of Enc-nZnO that are higher than those
used in the T47D viability experiments (80.1 ug/mL; 1 mM), the lipid coating appears to
protect the cells from the toxic effects of the nZnO. Even in areas with extremely high
concentrations of Enc-nZnO associated with the exterior of the cells (middle row), the
cell confluency is unaffected with little to no particles seen within the interior of the cell.
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This is in stark contrast to photo-irradiated cells treated with relatively low concentrations
of the Enc-nZnO (20.3 ug/mL; 250 μM; bottom row). In many of these cells, the
morphology of the membrane changes and appears to be compromised. Additionally, the
membrane stain doesn’t overlay with the particles as it does in Figure 5.2 or in the high
concentration Enc-nZnO /no UV treatment images (Figure 5.4, middle row). This
observation suggests that the particles shed the lipid coating upon photo-irradiation. In
addition, in localized areas of nZnO (bottom row), cell density is reduced and nZnO
appear to have internalized into the cells. These results confirm the viability profiles and
demonstrate the protective nature that the lipid coating has on the toxicity of nZnO.
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Figure 5.4
Confocal images of T47D breast cancer cells after 48 hours of
incubation in the imaging chambers and 24 hours post nZnO treatment. (Top Row)
T47D cells incubated in the absence of nZnO (negative control) to show lack of autofluorescence from the cells in the nZnO channel. The lipid membrane stain, CellMask
Orange was utilized to demonstrate the normal morphology of the cells (top-middle
panel). (Middle Row) T47D cells treated with 81.4 μg/mL (1 mM) of the encapsulated
nZnO (Enc-nZnO) 24 hours prior to imaging. These images demonstrate that even at
relatively high concentrations of the Enc-nZnO, the cells morphology doesn’t appear
to be affected suggesting that the toxicity of the NPs is negligible. (Bottom Row) T47D
cells treated with 20.3 μg/mL (250 μM) of Enc-nZnO and irradiated for 2 minutes
shows changes in the confluency of the cells and an apparent loss of cell membrane
integrity.
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Simulated and In Vitro Drug Release Experiments
Irradiation of nZnO with energy higher than the band gap of ZnO has been shown
to generate ROS.37 The ROS generating capabilities of nZnO have been proposed to be
produced from excited electrons in the conduction band reacting with adsorbed O2
molecules and locally adsorbed OH- interacting with valence band holes.37 We
hypothesized that irradiating the Enc-nZnO causes the nZnO to generate ROS which
leads to rapid and propagating lipid peroxidation and subsequently releases both nZnO
and any other cargo contained within the lipid carrier. To validate the triggered release
upon photo-irradiation, the fluorescent dye 5(6)-carboxyfluoroscein (CF) was used as a
hydrophilic drug model and co-encapsulated with the nZnO.
Fluorescent dyes are often used as a drug model by encapsulating high
concentrations of the dye within liposomes. High concentrations of fluorescent dyes lead
to a significant reduction of the fluorescent signal termed self-quenching. Upon release of
the dye into the suspending solution, the fluorescence is restored and this feature has been
extensively used as a model for drug loading. This approach allows for assessments of
drug release kinetics and entrapment efficiency.38-41 Using this model we demonstrated
the effect that the lipid to nZnO ratio has on the release kinetics and premature drug
release. As seen in Figure 5.5, lower lipid to nZnO ratios caused a much higher premature
drug leakage (Figure 5.5A, No UV). However, the triggered release of the dye was
drastically faster with low lipid to NP ratios (Figure 5.5B-C; 3:4 w/w) but the fluorescent
signal may be impacted by the premature release. The higher ratios of lipid to nZnO
almost entirely eliminated the premature release of the dye and reduced their release
kinetics. However, after only about 1 hour post irradiation, nearly the same amount of
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dye was released for the 5 minute exposure (Fig. 5.5 panel B), and nearly the same levels
of release were obtained for the 15 minute UV exposure groups (panel C).

Figure 5.5
(A-C) Release kinetics of encapsulated 5(6)-carboxyfluoroscein
(pH=7.4) and nZnO with various lipid to nZnO ratios (w/w). (A) Non-triggered
release (No UV) group, showing premature drug leakage from the different lipid to
nZnO ratios. (B) Release kinetics after 5 minutes of UV exposure. (C) Release kinetics
after 15 minutes of UV exposure. These release profiles demonstrate the majority of
the contents can be rapidly released within 60 minutes and provides insights into the
optimal lipid to NPs ratio. (D) nZnO encapsulated with a 5:4 lipid to NP ratio with an
internal pH=9.85. The higher pH is believed to allow the nZnO to produce more ROS,
thus allowing for a faster release of the dye with less irradiation time.
To try to improve upon the release kinetics, experiments were performed using a
higher pH (pH= 9.85) in the interior of the encapsulated nZnO/CF. The pH of the
environment has been shown to impact the ROS generating capabilities of irradiated
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nZnO.37 With a high pH, more hydroxides are present and it is believed that the valence
band holes left from the excited electron convert the locally adsorbed hydroxides to
hydroxyl radicals. Since we believe that the ROS generated from the irradiated nZnO is
responsible for the triggered release of the lipid coating, this strategy could increase the
overall release kinetics. Figure 5.5D utilized the 5:4 PC to nZnO (w/w) ratio and the
higher pH dramatically increased the release of the CF. Two minutes of UV exposure
generated similar but faster release kinetics than the 5 minutes of UV exposure when
using a pH of 7.4. Similarly, the release after 5 minutes of UV exposure was similar to
that of the 15 minute groups using a lower pH and 15 minutes of exposure induced a
faster and higher release than was achieved for any lipid to NP ratio previously.
Using CF as a drug model gave valuable insights into the release kinetics and how
both the lipid to nZnO ratio and pH altered the release profiles. However, we sought to
demonstrate the ability to co-encapsulate and release chemotherapy drugs using this
system. Since the fluorescent dye was an excellent model for hydrophilic drugs, we chose
to investigate the use of the hydrophobic drug Paclitaxel. Paclitaxel (PTX) is commonly
used in the treatment of various cancers such as non-small cell lung cancer and breast
cancer.42, 43 Due to its high hydrophobicity, the most widely used formulation of PTX
contains polyoxyethylated castor oil, which leads to numerous side effects including
hypersensitivity reactions.44, 45 This drawback has led to the development of new
formulations that include protein and lipid-based nanocarriers. Since lipid peroxidation is
proposed as the key to the triggered release mechanism in this system, the hydrophobic
lipid tails would become much more soluble in aqueous environments once peroxidation
occurs. This, in theory, would allow for a much faster release of PTX than in traditional
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lipid carriers since the drug would not be bound by the hydrophobic environment found
within the lipid bilayer. In pursuit of trying to develop a new carrier system and
demonstrate that both classes of drugs can be loaded, we treated both the Jurkat and
T47D cell lines with nZnO and Paclitaxel co-encapsulated (Enc-nZnO/PTX).
Figure 5.6 demonstrates that Paclitaxel and nZnO can be simultaneously delivered
within the lipid carrier. In the non-triggered release viability experiments (blue), the
Jurkat T cell viability profile was similar to the free PTX treatment (Figure 5.6A). While
this is consistent with reports that demonstrate that lipid carriers for PTX have similar
cellular viability profiles as using “free” PTX,46, 47 the triggered release groups (green)
showed a trend towards improvement in efficacy. Figure 5.6A used a higher ratio of
nZnO to PTX. The drop in viability could be due to a combined PTX and nZnO effect at
concentrations of nZnO that were previously shown to effect the viability of cells (>12.2
μg/mL; Figure 5.3). While simultaneous exposure to both nZnO and PTX could be
beneficial in the treatment of cancer, we also wanted to assess the efficacy when only
PTX effects are evident. To accomplish this, PTX was loaded with a lower nZnO to PTX
ratio (Figure 5.6B) to mitigate direct toxicity effects from nZnO. Even with
concentrations of nZnO that don’t impact the viability of the cells, an increase in toxicity
of the triggered release group was still achieved (Figure 5.6B). These findings
demonstrate that the triggered release of PTX from the lipid carrier improves the efficacy
of the drug (see Figure 5.6C for controls and comparison of the two ratios).
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Figure 5.6
Viability of Jurkat T cells after 48 hours of treatment with Paclitaxel
(PTX) co-loaded with the Enc-nZnO (Enc-nZnO/PTX) and various controls. (A) The
viability profile of the Jurkat cells when treated with free Paclitaxel and relatively
higher nZnO to PTX ratios. Comparing the released (UV Tx) vs. the non-released (No
UV) an increase in toxicity is noted for every concentration tested. (B) Relatively
lower nZnO to PTX ratios were utilized to demonstrate that increased toxicity is still
observed in the triggered release group at concentrations of nZnO that don’t impact
cell viability when used alone. (C) Treatments with the free drug PTX (5.0 nM), free
nZnO (8.1 μg/mL) and free nZnO/PTX (8.1 μg/mL-5.0 nM) compared with the EncnZnO/PTX (High nZnO 8.1 μg/mL; Low nZnO 2.0 μg/mL; PTX 5.0 nM) with and
without UV exposure.
To validate these findings, experiments were repeated in another cell type.
Surprisingly, T47D breast cancer cells demonstrated an even larger separation in viability
than Jurkat cells (Figure 5.7). Interestingly, at or above the 40 nM PTX concentration,

163
there was an extreme difference in the viability of the T47D cells when comparing the
UV vs. No UV groups. As this cell line behaved differently than the Jurkat cells, we
sought out to explain why there was such a striking difference in the viability profiles.
Our previous experiments with Enc-nZnO (no PTX; Figure 5.3C) showed no appreciable
difference in toxicity between the control and the irradiated groups at concentrations of
nZnO up to 16.3 μg/mL (200 μM). However, a ~40% difference was noted in the EncnZnO/PTX groups at this nZnO concentration (Figure 5.7A). It is possible that there
could be enhanced effects from co-treatment with both nZnO and PTX. As seen with the
controls in Figure 5.7B, the free nZnO had no effect on the viability profile, and the
treatment with free 40 nM PTX had a somewhat similar effect as the non-triggered
release Enc-nZnO/PTX group. Also, co-treatment with both the free nZnO and PTX had
no appreciable increase in toxicity, when compared to the PTX treatment alone. Thus, we
ruled out the possibility of additive or synergistic effects from nZnO and PTX at these
concentrations.

Figure 5.7
Viability profile of T47D breast cancer cells after 48 hours of treatment
of Enc-nZnO/PTX with and without UV irradiation. (A) The viability profile of the
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triggered release group (green) vs. the non-irradiated group (blue) shows striking
differences in toxicity. (B) Treatments with free nZnO (16.3 μg/mL), free PTX (40
nM) and free nZnO/PTX (16.3 μg/mL- 40 nM) compared to the Enc-nZnO/PTX (16.3
μg/mL- 40 nM). These controls demonstrate that at the 16.3 μg/mL concentration of
nZnO, the NPs/PTX have no added or synergistic effects when the T47D cells are
challenged with both the particles and PTX. Interestingly, a drastic improvement in
the drug’s efficacy is noted in the triggered release group, most likely due to localized
release of the drug in the vicinity of the cells.
Therefore, we believe this dramatic reduction in the viability is due to the fact that
the T47D cell line is adherent whereas the Jurkat cells are a suspension cell line. The
dispersion stability of the NPs most likely plays a role between these two cancer cell
model systems. Previous reports on nZnO and other NPs have demonstrated that
overtime the particles settle to the bottom of the culture wells, affecting the dosimetry
which can impact cell viability.34, 35 However, this alone cannot explain the differences in
toxicity because the same nZnO were used in the control groups. Since the phototherapy
was conducted 1.5 hours after the nZnO treatment, many of the particles likely settled to
the bottom of the well before the irradiation occurred. Indeed, the confocal images of the
Enc-nZnO treated T47D cells (Figure 5.4) demonstrate a high accumulation of the
encapsulated NPs in the local vicinity of the cells, further strengthening this argument.
When the PTX was rapidly released from the carrier due to photo-irradiation, this created
a much higher local concentration of the free drug near the cells that, in turn, created a
much higher cytotoxic response. These results also support the concept that the triggered
release of the same overall drug concentration near cancer cells can improve the efficacy
of the drug in the treatment of cancer.
Discussion
Lipid encapsulation of nZnO is an effective approach to stabilize them in ionic
solutions and effectively eliminate their toxicity. Using the inherent ability of nZnO to
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induce ROS when irradiated and thus releasing them to reassert their toxic effects, to our
knowledge, has never been demonstrated before. This strategy may further their potential
to be used as a therapeutic and the ability to co-load both hydrophilic and hydrophobic
drugs make this a promising delivery platform for the treatment of various diseases. The
extreme differences noted in the viability profiles of the T47D breast cancers cells where
surprising, yet offer much promise for this system to selectively target cancerous cells.
While we showed how some factors, such as the lipid ratio and the pH can improve the
release kinetics, other parameters may further enhance this approach.
The findings in this report utilizing UV to trigger the release of the liposomal
contents may find value in photodynamic therapy (PDT) treatment options such as in the
treatment of cancer.48 Further, the cargo of the lipid carrier is not limited to only
chemotherapeutic drugs, but could be used with drugs more traditionally used in PDT
that cause cell sensitivity to phototherapy. This may increase the uptake of the drug to the
targeted cells and reduce the patient’s overall sensitivity to light that is often reported
when treated with the free drug.49 Although using UV light as a source to induce ROS
generation from nZnO and induce the release of the cargo from the lipid carrier may be
appropriate in instances like these, it may not be practical in clinical settings for the
treatment of certain tumors found in deep tissue.
The depth penetration of UV light in tissue is in the high micrometer to low
millimeter range and therefore wouldn’t be able to penetrate large tumors. Many
researchers have therefore sought ways to use near-infared (NIR) light as a trigger release
mechanism as it has a higher depth penetration approaching the centimeter range.50
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While this avenue could be more effective than UV light, NIR light still lacks the depth
penetration needed for many tumors found in deep tissue areas.
Radiation therapy is extensively used in the treatment of tumors in all areas of the
body and high precision machines are now able to specifically target tumors with
relatively minimal radiation exposure to other tissues. Using X-ray or gamma rays as the
triggering mechanism would be an ideal method for the triggered release of the
encapsulated contents and may allow for simultaneous use of both radiation therapy and
the chemotherapy that is not advisable in certain situations. This mode of treatment may
also help combat drug resistant cells, as this would allow for simultaneous exposure of
radiation, the chemotherapy drug and nZnO. Other researchers have demonstrated
irradiating similar lanthanide doped nZnO with X-rays produces ROS, similar to UV
irradiation of pure nZnO.18 In addition to utilizing X-rays as a means to generate ROS
from gadolinium doped nZnO, other researchers have demonstrated the ability to use
these NPs as contrast agents for MRI and CT scans.18, 51 Utilizing this new drug delivery
system in combination with radiation therapy and potentially expanding its use for
imaging purposes would create a novel theranostic platform that would allow for
evaluations on tumor regression/progression during each therapy session.
In addition, reports have demonstrated with iron oxide NPs that the lipid carriers
can improve its negative contrast in MRI imaging,52 and may similarly improve the
contrast capabilities in this system. Since we have already demonstrated that
encapsulation of nZnO significantly reduces the toxicity of the NPs and with the recent
concerns about side effects using traditional gadolinium-based contrast agents, this
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system may potentially offer an alternative that has similar or improved imaging
capabilities but reduces the possible side effects associated with traditional contrast dyes.
Other future work will look into using monoclonal antibodies or targeting ligands
conjugated to the surface of the lipid carrier and could create a higher localized
concentration of the encapsulated NPs and drugs while simultaneously further enhancing
the contrast of the targeted tissue. Other encapsulating materials such as ROS sensitive
polymers and various other lipid compositions will be evaluated to optimize this drug
delivery platform. Since co-treatment with more than one chemotherapeutic drug is often
utilized in the treatment of cancer, loading more than one drug into the carrier would be
easily achievable and may provide a new way of co-administering multiple drugs. Using
ultra-sound is another feasible means to trigger the release of the carrier, as
sonoexcitation of nZnO has been shown to create ROS,53 and could extend the use of this
system to treat various diseases where irradiation may be a unadvisable. Lastly, other
synthesis methods that produce different nZnO structures could further enhance this
system, as hollow nZnO spheres have the capability of increasing the drug loading
potential.54 Collectively, there are many avenues to pursue using this technology and may
extend its use to the treatment of various diseases beyond cancer.
Conclusion
ZnO nanomaterials have received considerable attention due to many promising
attributes and increasing applications in the treatment of diseases. This paper
demonstrates a new approach to utilizing the ROS generating properties of nZnO and
potentially other metal oxide NPs for drug delivery and possible imaging applications.
The lack of apparent toxicity of the encapsulated nZnO and re-establishment of its anti-
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cancer activity in the triggered release group is a step towards the goal of selectively
treating cancer while preventing harm to normal cells. The extreme differences noted in
the viability profiles of the T47D breast cancer cells treated with the co-encapsulated
nZnO and Paclitaxel demonstrate the potential this system has for the co-delivery of
multiple chemotherapeutics with on-demand release. Extending this system to utilizing
X-rays to trigger the release is promising but much work is still required to optimize this
platform before moving on to animal models and clinical studies. Many parameters such
as the encapsulation composition, conjugation of ligands and making the particles stealth
to the immune system are just of few of the key features that need to be addressed.
However, with the foundation laid, the aim of utilizing this system for the treatment of
various diseases and specifically cancer appears achievable.
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Supporting Information

Figure S5.1 Self quenching curve of 5(6)-Carboxyfluorescein in 130 mM NaCl.
Concentrations below 1.5 µM show a linear increase in intensity vs. concentration.
Working below this concentration allowed for evaluations on the release kinetics of
the dye that was co-encapsulated with nZnO.

Figure S5.2 NPs size distributions from DLS measurements. (a) Bare nZnO
suspended in nanopore water. (b) Bare nZnO suspended in 130 mM NaCl. (c) Lipid
encapsulated nZnO suspended in 130 mM NaCl. nZnO suspended in nanopore water
shows a broad distribution between 100 and 1000 nm. In the salt solution the bare
NPs agglomerate into much larger sizes in the micrometer range. Encapsulating the
nZnO in lipids prevents the NPs from agglomerating into the large particles even in
the 130 mM NaCl solution with their size distribution similar to that of bare nZnO in
nanopore water.
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Figure S5.3 XPS scan of the NPs before encapsulation showing no other elements
besides zinc, oxygen and carbon are present. FTIR spectra confirms the sample purity
seen with XPS measurements. The main peak near 500 cm-1 is from the Zn-O modes.
The other broad peak near 3400 cm-1 is from O-H and the other minor peaks are
attributed to carbon dioxide.
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CHAPTER SIX: CONCLUSION
The low cost of production and vast array of potential uses for nZnO make them a
promising material in the field of nanobiotechnology. Specifically, their use as a potential
therapeutic and diagnostic tool offer much hope as a new nanomedicine. To be able to
fully exploit their use, their mechanism of toxicity and how various properties modulate
their interactions with cells needs to be clearly understood. This dissertation explored
various factors that contribute to the toxicity of nZnO and how their physical properties
can be harnessed for their use in imaging and as a therapeutic.
The discovery that biological buffers induce the rapid dissolution of nZnO may
help in elucidating the toxicity mechanism of nZnO by eliminating artifacts associated
with their use. Additionally, understanding how the use of these buffers impact their
transformation into different chemical species and complex precipitants provided a
clearer picture of how they behave in various toxicological studies. These results
highlight the need for researchers to clearly identify the use of these buffers in their
experiments and consider how their inclusion my impact conclusions when performing
evaluations on nZnO toxicity.
Use of the pore-forming toxin lysenin demonstrated that using a simplified model
system for voltage-gate ion channels is an excellent tool for investigating how nZnO may
interact with protein channels and subsequently alter their functionality. The findings that
nZnO can significantly inhibit the conductance of lysenin channels suggests that
electrostatic interactions between nZnO and transmembrane transporters may impact the
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transporters functionality, thus contribute to the toxicity of nZnO. While this finding
might be considered another factor that could impede the use of nZnO, these results may
find use in nanomedicine and drug delivery applications to regulate the gating of specific
ion channels.
The ability to control certain defect states in nZnO was an exciting achievement
as it altered the physical properties of the nanoparticles, creating a narrow visible
emission and lowered the band gap of the material. These features made it possible to use
common fluorescent imaging instruments, such as a confocal microscope, to perform
live-cell imaging experiments. These new nZnO provide a new way to track the NPs
interactions with cells in real-time as well as potentially develop into a new alternative
bio-label. Additional experiments utilizing these nZnO have the potential to help decipher
the complex interplay of nZnO with various cell types and expand their use in other
nanobiotechnology applications.
The final investigation into using the ROS generating properties of nZnO in a new
drug delivery platform showed tremendous potential. The nearly complete elimination of
the nZnO toxicity through encapsulation demonstrated a simplistic way to potentially
eliminate any off-target effects from nZnO if used as a therapeutic. The additional ability
to trigger the release of the nanoparticles and drugs offers the promise to create a site
specific and on-demand targeting system for the treatment of various diseases. The
dramatic decrease in the viability of the breast cancer cells in the triggered release group
exemplified the concept that releasing the payload near cancerous tissue can significantly
improve the efficacy of the drug in the treatment of cancer.
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Collectively, the different investigations in this dissertation improved the
understanding of nZnO toxicity and offer new ways to use different properties of nZnO in
biological applications. Further work is required to fully exploit these new findings, but
the foundations laid here provide the basis for their use in novel ways. Continued
improvement on these new technologies may extend these systems into in vivo
experiments, clinical trials and hopefully into a therapeutic.
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